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MAMMALIAN MULTIPOTENT STEM CELLS
AND COMPOSITIONS, METHODS OF
PREPARATION AND METHODS OF
ADMINISTRATION THEREOF

Publication Nos. WO 93/01275, WO 94/09119, WO
94/10292, WO 94/16718 and Cattaneo et al., 1996, Mal.
Brain Res. 42: 161-66. NSCs from the embryonic and adult
rodent central nervous system (CNS) have been isolated and
further propagated in vitro in a variety of culture systems.
See, e.g., Frolichsthal-Schoeller et al., 1999, NeuroReport 10:
345-351; Doetsch et al., 1999, Cell 97: 703-716. NSCs from
the human fetal brain have been cultured using serum-free
medium supplemented with epidermal growth factor (EGF)
and/or basic fibroblast growth factor (bFGF). See, e.g.,
Svendsen et al., 1998, J. Neuroscience Methods 85: 141-152;
Carpenter et al., 1999, Experimental Neurology 158: 265278. NSCs cultured utilizing these serum-free, mitogensupplemented methods generally form substantially undifferentiated, clustered aggregates. Upon removal of the
mitogen(s) and provision of a substrate, the stem cells differentiate into neurons, astrocytes and oligodendrocytes.
While the synaptic connections involved in neural circuits
are continuously altered throughout the life of the individual,
due to synaptic plasticity and cell death, neurogenesis, the
generation of new neurons, was thought to be complete early
in the postnatal period. The discovery ofMNSCs in the adult
brain (see, e.g., Alvarez-Buylla et al., 1997, J. Neurobiology
33: 585-601; Gould et al., 1999, Science 286: 548-552) has
brought significant changes in the theory on neurogenesis as
the presence ofMNSCs in the adult brain suggests that regeneration of neurons can occur throughout life. Nevertheless,
age, physical and biological trauma or neurodegenerative
disease-associated loss of brain function, herein referred to as
a "neurological deficit," can far outweigh any potential restorative effects due to endogenous neurogenesis. As a result,
transplantation ofNSCs is a potentially valuable treatment for
those suffering from the loss of, or loss of appropriate, brain
function due to age, physical and biological trauma or neurodegenerative disease (i.e., a neurological deficit).
Due to the advancing average age of the population, and
concomitantly increased incidence of neurological deficit
that accompanies advancing age, treatment of neurodegenerative diseases has become a major concern. Such diseases,
including Alzheimer's disease, Huntington's chorea and Parkinson's disease, have been linked to neuronal degeneration
at specific locations in the brain, leading to the inability of the
brain region to synthesize and release neurotransmitters that
are vital to neuronal signaling.
Neurodegeneration also encompasses many conditions
and diseases, age-related or not, that result in neuronal loss.
These conditions include CNS trauma, such as stroke and
epilepsy, as well as diseases that result in neuronal loss,
including amyotrophic lateral sclerosis and cerebral palsy.
Degeneration in a brain region known as the basal ganglia
can lead to diseases with varied and different cognitive and
motor symptoms, depending on the exact location of the
lesion. The basal ganglia consists of many separate regions,
including the striatum (which consists of the caudate and
putamen), the globus pallidus, the substantia nigra, substantia
innominata, ventral pallidum, nucleus basalis of Meynert,
ventral tegmental area and the subthalamic nucleus.
Degeneration in the basal ganglia can lead to motor deficits. For example, Huntington's chorea is associated with
degeneration of neurons in the striatum, which leads to involuntary jerking movements. Degeneration of a small region
called the subthalamic nucleus is associated with violent
flinging movements of the extremities in a condition called
ballismus, while degeneration in the putamen and globus
pallidus are associated with a condition of slow writhing
movements or athetosis. In Parkinson's disease, degeneration
is seen in another area of the basal ganglia, the substantia

This application is related to U.S. Provisional Patent Applications Ser. No. 60/348,473, filed Jan. 14, 2002, and Ser. No.
60/357,783, filed Feb. 19, 2002, and Ser. No. 60/376,257,
filed Apr. 29, 2002, and Ser. No. 60/381,138, filed May 8,
2002, and Ser. No. 60/404,361, filed Aug. 19, 2002, and Ser.
No. 60/430,381, filed Dec. 2, 2002, the disclosures of each of
which are expressly incorporated by reference herein.
This invention was made with support from the U.S. Govermnent through the National Institutes of Health, grant no.
R03-AG19874. The govermnent has certain rights in this
invention.
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BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel mammalian multipotent
stem cells (MSCs), compositions thereof, and methods of
preparing and administering these cells. In one aspect, the
invention relates to methods of making more developmentally potent cells from less developmentally potent cells. In
another aspect, the invention relates to cells prepared according to the methods of the invention. In another aspect, the
invention relates to pharmaceutical compositions comprising
the more developmentally potent cells of the invention. In
another aspect, the invention relates to cellular preparations
for cell or tissue regeneration comprising said more developmentally potent cells of the invention. In another aspect, the
invention relates to methods for regenerating cells or tissue
comprising the step of administering the more developmentally potent cells of the invention to a tissue in an animal in
need thereof. In another aspect, the invention relates to a
method for treating a human or animal having a neurological
or corporal deficit comprising the step of administering the
more developmentally potent cells of the invention or terminally differentiated cells produced according to the invention
to an animal, including human, in need thereof. In another
aspect, the invention relates to a method of making and using
a terminally differentiated cell utilizing the more developmentally potent cells of the invention. In another aspect, the
invention relates to a method of changing the phenotype of a
cell.
2. Background of the Related Art
Stem cells are often defined as self-renewing and multipotent, with the ability to generate diverse types of differentiated
cells. As such, they show promise in the treatment ofneurological and corporal deficits, or any loss or diminishment of
tissue function due to age, disease, trauma or other factor.
However, such treatments have faced significant hurdles that
have yet to be substantially overcome.
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NSCs and Neurological Deficits
Because one important focus of stem cell replacement
therapies has been neurological disorders, neural stem cells,
and particularly fetal neural stem cells, have been a major
research target. During development of the central nervous
system (CNS), multipotent neural stem cells (MNSCs), also
known as neural stem cells (NSCs ), proliferate, giving rise to
transiently dividing progenitor cells that eventually differentiate into the cell types that compose the adult brain, including
neurons, astrocytes and oligodendrocytes. NSCs have been
isolated from several mammalian species, including mice,
rats, pigs and humans. See, e.g., International Application,
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nigra par compacta. This area normally sends dopaminergic
connections to the dorsal striatum, which is important in
regulating movement. Therapy for Parkinson's disease has
centered upon restoring dopaminergic activity to this circuit.
Alzheimer's disease patients exhibit a profound cellular
degeneration of the forebrain and cerebral cortex. Further, a
localized area of the basal ganglia, the nucleus basalis of
Meynert, appears to be selectively degenerated. This nucleus
normally sends cholinergic projections to the cerebral cortex
that are thought to participate in cognitive functions including
memory.
The objective of most CNS therapies is to regain the particular chemical function or enzymatic activity lost due to
cellular degeneration. Administration of pharmaceutical
compositions has been the main treatment for CNS dysfunction. Unfortunately, this type of treatment has many complications, including the limited ability to transport drugs across
the blood-brain barrier, and drug-tolerance acquired by
patients to whom these drugs are administered for long periods.
Transplantation of multipotent stem cells may avert the
need not only for constant drug administration, but also for
complicated drug delivery systems necessitated by the bloodbrain barrier. In practice, however, significant limitations
have been found in this technique as well. First, cells used for
transplantation that carry cell surface molecules of a differentiated cell from a donor can induce an immune reaction in
the recipient, a problem that is exacerbated by the physical
damage caused by injection of cells directly into the affected
area of the brain. In addition, the neural stem cells must be at
a developmental stage where they are able to form normal
neural connections with neighboring cells. For these reasons,
initial studies on neurotransplantation centered on the use of
fetal cells.
Manimalian fetal brain tissue has proven to have reasonable survival characteristics upon immediate transplantation.
Increased survival capability of fetal neurons is thought to be
due to the reduced susceptibility of fetal neurons to anoxia
compared to adult neurons. An additional factor favoring
survival of fetal cells is the lack of cell surface markers on
fetal cells, whose presence may lead to rejection of grafted
tissue from adults. However, although the brain is considered
an immunologically privileged site, some rejection of even
fetal tissue can occur. Therefore, the ability to use heterologous fetal tissue is limited by tissue rejection and the need for
immunosuppressant drugs.
The use of large quantities of aborted fetal tissue presents
other difficulties as well. Fetal CNS tissue is composed of
more than one cell type, and thus is not a well-defined tissue
source. In addition, there are doubts as to whether an adequate
and constant supply of fetal tissue would be available for
transplantation. For example, in the treatment of MPTP-induced Parkinsonism, tissue from as many as 6 to 8 fetuses can
be required for successful implantation into the brain of a
single patient. There is also the added problem of the potential
for contamination during fetal tissue preparation. Since these
tissue may already be infected with a bacteria or virus, expensive diagnostic testing is required for each fetus used. Even
comprehensive diagnostic testing might not uncover all
infected tissue. For example, there can be no guarantee that a
sample is HIV-free, because antibodies to the virus are generally not present until several weeks after infection.
In addition to fetal tissue, there are other potential sources
of tissue for neurotransplantation, including cell lines and
genetically engineered cell types, but both sources present
problems. Cell lines are immortalized cells that are derived,
inter alia, by transformation of normal cells with an oncogene

or by the culturing of cells in vitro with altered growth characteristics. Moreover, adverse immune response potential,
the use of retroviruses to immortalize cells, the potential for
the reversion of these cells to an amitotic state, and the lack of
response by these cells to normal growth-inhibiting signals
make such cell lines sub-optimal for widespread use. Likewise, xenobiotic transplantation has lacked significant success.
Another approach to neurotransplantation involves the use
of genetically engineered cell types or gene therapy. However, there still exists a risk of inducing an immune reaction
with these cells. In addition, retrovirus mediated transfer may
result in other cellular abnormalities. Also, cell lines produced by retrovirus-mediated gene transfer have been shown
to gradually inactivate their transferred genes following
transplantation and further may also not achieve normal neuronal connections with the host tissue.
While currently available transplantation approaches represent an improvement over other available treatments for
neurological disorders, they suffer from significant drawbacks. The inability in the prior art of the transplant to fully
integrate into the host tissue, and the lack of availability of
suitable cells in unlimited amounts from a reliable source for
grafting are significant limitations of neurotransplantation.
Studies utilizing intra-tissue injection of dissociated and partially differentiated NS Cs have shown little promise (see, e.g.,
Benninger et al., 2000, Brain Pathol. 10: 330-341; Blakemore
et al.. 2000, Cell Transplant 9: 289-294; Rosser et al., 2000,
Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000, Mal. Cell
Neurosci. 16: 1-13). The results have generally been poor
because, among many considerations, the dissociation of
clusters ofNSCs is known to cause immediate senescence of
the NSCs and increase the vulnerability ofNSCs in culture.
See, e.g., Svendsen et al., 1998, J. Neurosci. Methods 85:
141-152. Further, regardless of adverse immune responses
due to foreign tissue being introduced into the brain, the
trauma caused by the physical introduction of cells directly
into the damaged area can induce the recruitment of immune
cells by the host that can eliminate the transplanted cells.
Thus, significant problems with the use ofNSCs to ameliorate
neurological deficits remain.
As described herein, neurological deficits also include
non-brain tissues such as, for example, the eye and spinal
cord. In addition, corporal deficits are a target for amelioration utilizing multipotent stem cells. A "corporal deficit" is a
disorder caused by a wide variety of diseases and injuries,
resulting in trauma, malfunction, degeneration or loss of
muscle such as, for example, cardiac muscle due to myocardial infarction. Other examples include malfunction, degeneration or loss of other cells and tissues apart from those
discussed in the neurological deficit section above such as, for
example, internal organs. For example, liver function can be
adversely affected by, among other things, disease (e.g., cirrhosis or hepatitis), trauma or age. The problems described
above in using NSCs to remedy neurological deficits of the
brain also apply to neurological deficits in other tissues, such
as the eye, and corporal deficits.
There exists a need in the art for improved methods for
introducing multipotent stem cells to diseased, aged or damaged mammalian brain. In addition, there remains a need for
methods of using or administering the multipotent stem cells
of the invention, or pharmaceutical preparations thereof, to
the affected, damaged or degenerated tissue, wherein the stem
cells can differentiate in a manner appropriate for the host
tissue and enable the replacement of damaged cells, repair of
damages tissue and, optionally, amelioration of functional
loss. There also remains a need in the art for a reliable source
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of unlimited numbers of cells for transplantation, particularly
cells that are specifically adapted for and capable of proliferation, migration, and differentiation in marmnalian brain or
other tissues when introduced thereto. Furthermore, there
exists a need in the art for methods for repairing damaged
neural and other tissues in as non-invasive a fashion as possible, especially by inducing multipotent stem cells to proliferate and differentiate in vivo into, for example, neurons,
astrocytes, and oligodendrocytes in the brain or, for example,
rod or cone photoreceptor cells, horizontal cells, bipolar cells,
amacrine cells, ganglion cells, Muller cells, and nerve cells,
Buchs, chorid and retinal pigment epithelium (RPE) cells in
eye tissue.

developmentally potent cell is obtained from any tissue containing stem cells including but not limited to zygote, blastocyst, embryo, fetus, infant juvenile or adult, and optionally, a
human species ofany of the preceding embodiments, whether
naturally occurring or engineered. As provided herein, the
methods of the invention provide one or a plurality of more
developmentally potent cells that exist singly or form clusters
of two or more cells.
In the practice of this aspect of the invention, the phenotype
of the less developmentally potent cell is changed when it
becomes a more developmentally potent cell. Thus, the invention provides methods for changing a first phenotype of a less
developmentally potent cell into a second phenotype of more
developmentally potent cell, wherein said second phenotype
is determined by the environment surrounding the substituted
deoxynucleotide or deoxynucleoside-contacted cell. In preferred embodiments, the less developmentally potent cell is a
stem cell, more preferably a hematopoietic stem cell, a neural
stem cell, an epithelial stem cell, an epidermal stem cell, a
retinal stem cell, an adipose stem cell and a mesenchymal
stem cell.
In a second aspect, the invention provides one or a plurality
of more developmentally potent cells using the methods of
the invention. In certain embodiments, the cells form a cluster
of two or more cells. As provided herein, said more developmentally potent cells preferably comprise less than about 50
percent, more preferably less than about 25 percent, even
more preferably less than about 10 percent, even more preferably less than about 5 percent, and even more preferably
less than about 1 percent redifferentiated cells. "Redifferentiated cells" as used herein, refers to cells that have terminally
differentiated during the performance of the methods herein
prior to migration, differentiation and incorporation into host
tissue.
In yet further aspects of the invention are provided pharmaceutical compositions comprising said more developmentally potent cells prepared according to the methods of the
invention and a pharmaceutically-acceptable carrier or
excipient. The invention provides such pharmaceutical compositions comprising said more developmentally potent cells
that are tissue stem cells for use in cell or tissue regeneration
or for correcting a disease or disorder in a tissue or animal in
need thereof.
Thus, the invention also provides methods for using the
pharmaceutical compositions provided herein to treat an animal in need thereof by administering the more developmentally potent cells thereto. In certain preferred embodiments,
the more developmentally potent cells comprise a cluster of
two or more of the more developmentally potent cells. Preferably, the animal has a corporal or neurological deficit that
can be treated or ameliorated by administration of said more
developmentally potent cells, such as a deficit caused by a
neurodegenerative disease, a traumatic injury, a neurotoxic
injury, ischemia, a developmental disorder, a disorder affecting vision, an injury or disease of the spinal cord, a demyelinating disease, an autoimmune disease, an infection, an
inflammatory disease, or corporal disease, disorder, injury,
trauma, malfunction, degeneration or loss. In preferred
embodiments, the one or plurality of more developmentally
potent cells are capable of migrating to an area of tissue
damage, differentiating in a tissue-specific manner and functioning in a manner that reduces the neurological or corporal
deficit. As provided by the methods of the invention herein,
the cells are administered by injecting one or a plurality of
more developmentally potent cells with a syringe, inserting
the more developmentally potent cells with a catheter or
surgically implanting the more developmentally potent cells.

SUMMARY OF THE INVENTION
This invention provides methods for producing multipotent stem cells, and cells produced by those methods. In
particular, the invention provides reagents and methods for
efficiently producing stem cells that can be re-introduced into
an animal in need thereof to alleviate neurological or corporal
disorders.
In a first aspect, the invention provides methods for making
a more developmentally potent cell from a less developmentally potent cell. In one embodiment, the method comprises
the step of contacting a less developmentally potent cell with
an effective amount of a substituted deoxynucleotide or
deoxynucleoside compound for an effective period, wherein
the substituted deoxynucleotide or deoxynucleoside compound-contacted, less developmentally potent cell becomes a
more developmentally potent cell capable of differentiating
to a less developmentally potent cell of its lineage of origin or
a different lineage. In certain embodiments, the inventive
methods further comprise the step of co-culturing the less
developmentally potent cell contacted with substituted
deoxynucleotide or deoxynucleoside compounds with neural-lineage cells or media conditioned with neural-lineage
cells, wherein the substituted deoxynucleotide or deoxynucleoside compound-contacted, less developmentally
potent cell becomes a more developmentally potent cell
capable of differentiating to a less developmentally potent
cell of its lineage of origin or a different lineage. In additional
embodiments, the method comprises the step of contacting
the less developmentally potent cell with a substituted deoxynucleotide or deoxynucleoside compound in an uncoated
flask or a flask that has been treated to repel the cells. In yet
further embodiments, the less developmentally potent cell is
further contacted with a growth factor such as fibroblast
growth factor, epidermal growth factor or a combination
thereof. Alternatively, the less developmentally potent cells
are contacted additionally with heparin.
Exemplary substituted deoxynucleotide or deoxynucleoside compounds as provided by the invention include but are
not limited to halogen-substituted (halo-substituted) deoxynucleotides or deoxynucleosides, such as, for example, bromodeoxyuridine, iododeoxyuridine, bromodeoxyguanosine,
iododeoxycytosine as well as alkyl-substituted species such
as, for example, methyldeoxythymidine. A most preferred
species is bromodeoxyuridine (BrdU). In certain embodiments, the less developmentally potent cell is contacted with
an effective amount of substituted deoxynucleotide or deoxynucleoside compounds for an effective period. In some
embodiments, the less developmentally potent cell is a tissue
(or tissue-specific) stem cell, such as a hematopoietic stem
cell, a neural stem cell, an epithelial stem cell, an epidermal
stem cell, a retinal stem cell, an adipose stem cell and a
mesenchymal stem cell. In certain embodiments, the less
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In certain embodiments, the more developmentally potent
cells are injected with a syringe into a body cavity that is
fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. In other embodiments, the more developmentally potent cells are inserted with a catheter into a body cavity
that is fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity
is a brain ventricle. In still further additional embodiments,
the more developmentally potent cells are surgically
implanted into a body cavity that is fluidly-connected to the
area of neurological or corporal deficit. In certain preferred
embodiments, the body cavity is a brain ventricle. The more
developmentally potent cells can also alternatively be
inserted using a syringe or catheter or surgically implanted
directly at the site of the neurological or corporal deficit or
systemically (e.g., intravenously).
Administration of the one or a plurality of more developmentally potent cells into an animal results in said cells differentiating into a terminally-differentiated cell. Thus, the
invention provides methods for making a terminally-differentiated cell, comprising the step of administering the more
developmentally potent cells of the invention into an animal
in need thereof. As provided by the methods of the invention
herein, the cells are administered by injecting the more developmentally potent cells with a syringe, inserting the more
developmentally potent cells with a catheter or surgically
implanting the more developmentally potent cells. In certain
embodiments, the more developmentally potent cells are
injected with a syringe into a body cavity that is fluidlyconnected to the area of neurological or corporal deficit. In
certain preferred embodiments, the body cavity is a brain
ventricle. In other embodiments, the more developmentally
potent cells are inserted with a catheter into a body cavity that
is fluidly-connected to the area of neurological or corporal
deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. In still further additional embodiments, the
more developmentally potent cells are surgically implanted
into a body cavity that is fluidly-connected to the area of
neurological or corporal deficit. In certain preferred embodiments, the body cavity is a brain ventricle. The more developmentally potent cells can also alternatively be inserted
using a syringe or catheter or surgically implanted directly at
the site of the neurological or corporal deficit or systemically
(e.g., intravenously).
In the practice of this aspect of the invention, the phenotype
of the more developmentally potent cell is changed when it
differentiates into a terminally-differentiated cell. Thus, the
invention provides methods for changing a first phenotype of
a more developmentally potent cell into a second phenotype
ofless developmentally potent, more preferably a terminallydifferentiated cell. The method further provides a method for
changing a developmental potential phenotype of a cell, comprising the steps of contacting a cell of a first developmental
potential phenotype with an effective amount of substituted
deoxynucleotide or deoxynucleoside for an effective period
that causes the cell to change into a second developmental
potential phenotype distinct from the first developmental
potential phenotype, wherein said second developmental
potential phenotype is determined by the environment surrounding the substituted deoxynucleotide or deoxynucleoside contacted cell. In certain embodiments, the cell of a first
developmental potential phenotype can be a stem cell. In
other embodiments, the cell of a first developmental potential
phenotype can be a hematopoietic stem cell, a neural stem
cell, an epithelial stem cell, an epidermal stem cell, a retinal

stem cell, an adipose stem cell and a mesenchymal stem cell,
in preferred embodiments a mesenchymal cell.
Alternatively, the invention provides a method of treating a
patient having a neurological deficit or corporal deficit with
terminally differentiated cells, that is, with cells that are terminally differentiated prior to administration. Such terminally differentiated cells can be administered at the site of
neurological or corporal deficit or systemically, for example,
intravenously.
In yet another embodiment, the invention relates to treating
a stem cell, excluding those of neural origin, such that it is
converted into a more developmentally potent cell, which
enables it to differentiate into the various cell types found in
eye tissue, inter alia, chorid, Buchs and retinal pigment epithelium cells, rod and cone photoreceptor cells, horizontal
cells, bipolar neurons, amacrine, ganglion and optic nerve
cells. These non-limiting, exemplary cell types found in eye
tissue are collectively referred to as retinal cells. The methods
comprising the step of contacting more developmentally
potent cells of the invention with an effective amount of one
or a combination of growth factor selected from the group
consisting of TGF-b3, IGF-1 and CNTF for an effective
period such that the growth factor-contacted cells can differentiate into retinal cells.
In another aspect, the invention provides a method of altering the migration and/or differentiation of endogenous or
exogenous multipotent stem cells in a mammal by modulating the levels of APP and/or reelin in the mammal. In certain
embodiments, the exogenous multipotent stem cells can be
the more developmentally potent cells produced according to
the methods of the invention. In certain other embodiments,
the more developmentally potent cells are administered as
part of the pharmaceutical compositions or the cellular preparations of the invention. In other embodiments, the amount of
reelin in a manimal is altered by administration of reelin
protein, a drug that alters reelin levels, or a vector that
expresses reelin to the mammal. In still other embodiments,
the amount of APP in a manimal is altered by administration
of an anti-APP antibody, a drug that alters APP levels, a vector
that expresses APP, or the APP protein to the mammal. In still
other embodiments, reelin can be administered before, after
or concurrently with the more developmentally potent cells of
the invention. Similarly, in other embodiments, anti-sAPP
antibody or s-APP (secreted APP) can be administered
before, after or concurrently with the more developmentally
potent cells of the invention. In related embodiments, the
invention provides methods of altering the migration of
endogenous or exogenous multipotent stem cells in a mammal by altering the amount or binding affinity ofAPP or reelin
receptor in the mammal. Similarly, the invention provides a
method of altering the differentiation of endogenous or exogenous multipotent stem cells in a mammal by altering the
amount or binding affinity of APP receptor in the mammal.
In another aspect, the invention provides a method of making a differentiated cell-specific product comprising the steps
of differentiating the more developmentally potent cells of
the invention, in the presence of an effective amount of factors
known to induce differentiation of the desired cell type and
isolating the desired differentiated cell-specific product. In
another embodiment, the invention provides a method of
making an undifferentiated cell-specific product comprising
the steps of propagating the more developmentally potent
cells of the invention according to the methods of the invention and isolating the desired undifferentiated cell-specific
product.
Thus, the invention advantageously provides novel mammalian multipotent stem cells, pharmaceutical compositions
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thereof, and methods of preparing and administering the
cells. The invention also advantageously provides methods of
altering the migration and/or differentiation of multipotent
stem cells through the alteration of APP and reeling levels.
Further, the invention advantageously provides methods of
utilizing the methods and cells of the invention to produce
biochemical products.
Specific embodiments of the present invention will become
evident from the following more detailed description of certain preferred embodiments and the claims.

entiated into bIII-tubulin positive cells (green), in CAI pyramidal cell layer. These bIII-tubulin positive cells have BrdU
positive nuclei (red), indicating that these cells originated
from transplanted cells. In contrast, host cell nuclei counter
stained with DAPI (blue) are not bIII-tubulin positive. (e) In
the dentate gyrus many fibers were bIII-tubulin positive in
addition to the bIII-tubulin positive cells (green) and GFAP
positive cells (red). (f) bIII-tubulin positive cells (green) and
GFAP positive cells (red) were found in layer IV and layer III,
respectively. Such a layer of astrocytes were not observed in
normal rats without MNSC transplantation.
FIG. 5 shows co-localization of bIII-tubulin (a neuronal
marker) and BrdU immunoreactivity in the same cells. (a-c)
Three different planes of the same microscopic view. The bIII
-tubulin positive cells (green) show BrdU positive nuclei
(red) indicating that these cells are derived from transplanted
NSCs.
FIG. 6(I) shows the immunohistochemistry of differentiated human MNSCs using antibodies against bIII-tubulin (a)
and glial fibrillary acidic protein (GFAP) (b ). FIG. 6(II)
shows the differentiation of MNSCs in the co-culture with
oxidatively damaged SH-Sy5 human neuroblastoma: (from
left to right) light gray bars=control (0.0 µM H 2 0 2 ); medium
gray bars=low H 2 0 2 (0.01 µM); dark gray bars=medium
H 2 0 2 (0.03 µM); black bars=high H 2 0 2 (0.1 µM).
FIG. 7 shows spontaneous differentiation of MNSCs in
serum-free basal media. Mixed populations of differentiating
cells are coronally migrating outward from a cluster of cells
located on the top of the picture.
FIG. 8 shows fluorescent immunocytochemistry of differentiated human MNSCs (a) and MeSCs (b) of the invention.
bIII-tubulin (green) and GFAP (red) immunoreactivity indicate neuronal and glial differentiation, respectively. Nuclei
counter-staining with DAPI is shown in blue.
FIG. 9 shows typical fluorescent immunohistochemical
photomicrographs in rat brain 4-6 weeks after transplantation
of more developmentally potent MeSCs of the invention.
bIII-tubulin immunoreactivity was used as a neuronal marker.
Since MeSCs were treated with BrdU before transplantation,
transplanted cells have BrdU positive nuclei (red). MeSCs
migrated into the cortex and differentiated into neurons as
indicated by the bIII-tubulin positive cells (green), which
have morphologies typical of pyramidal cells (a, b ). All the
human specific bIII-tubulin (green) positive cells show BrdU
(red) positive nuclei while many other host cell nuclei are
stained with only DAPI (blue). Apical dendrites were wavy
compared with the neurons differentiated from MNSCs but
pointed towards to the edge of the cortex. MeSCs tend to have
larger nuclei than host cells. MeSCs migrated into the hippocampus and differentiated into bIII-tubulin positive cells
(green), in CAI pyramidal cell layer (c-h). These bIII-tubulin
positive cells have BrdU positive nuclei (red), indicating that
these cells originated from transplanted cells. In contrast, host
cell nuclei counter stained with DAPI (blue) are not bIIItubulin positive. At four weeks post transplantation (c,d), the
bIII-tubulin positive cells show bipolar neuronal morphology
and may still be migrating to the pyramidal cell line. At 5
weeks post transplantation, some of the cells have already
reached the pyramidal cell line and have started to change
morphologies. At six weeks post transplantation (g,h), the
cells start to show pyramidal cell like morphologies.
FIG.10 shows differentiation ofMeSCs into retinal cells in
vivo. All nuclei were counterstained by DAPI (blue). (a)
Typical immunocytochemistry of retinal sections 4 weeks
after a lesion and transplantation of MeSC of the invention
(xi 00). The section was double-immunofluorescence stained
with BrdU (red) and ops in (green) markers for donor cells and
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BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee, pursuant to 37 C.F.R. §1.84.
FIG. 1 shows a phase contrast photomicrograph of a floating, aggregated cluster of cells, characteristic of certain
embodiments of the cells of the invention.
FIG. 2 shows the effect of MNSC transplantation on
memory score in the Morris water maze test. (a) Individual
memory score before and after transplantation shows
improvement in the majority of the animals. Blue: Aged
memory impaired animals, Green: Aged memory unimpaired
animals, Red: Matured animals. (b) Mean of memory score in
each animal group before (narrow striped bar) and after
(black bar) MNSCs transplantation shows a significant
improvement in aged memory impaired and young animals.
The animals that received vehicle injection do not show significant difference in memory score between before (wide
striped bar) and after (hatched) the injection.
FIG. 3 shows differentiation ofMeSCs into retinal cells in
vivo. All nuclei were counterstained by DAPI (blue). (a)
Typical immunocytochemistry of retinal sections 4 weeks
after a lesion and transplantation of MeSC of the invention
(xi 00). The section was double-immunofluorescence stained
with BrdU (red) and op sin (green) markers for donor cells and
photoreceptor cells, respectively. MeSCs of the invention
migrated into damaged area of the retinal tissue. A higher
magnification (b, x400) shows that these migrating MeSCs
also show cytosolic expression of op sin. (c) Typical in situ
hybridization histochemistry (xlOO) for human opsin gene
expression using human-specific opsin sequence riboprobes
(green). Incorporation ofhuman opsin positive cells to the rat
retinal tissue is observed.
FIG. 4 shows typical fluorescent immunohistochemical
photomicrographs of aged rat brain 30 days after MNSCs
transplantation. bIII-tubulin and GFAP immunoreactivity
were used as markers for neuron and glia, respectively. (a)
MNSCs of the invention migrated into the cortex and differentiated into neurons as indicated by the bIII-tubulin positive
cells (green), which have morphologies typical of pyramidal
cells in layer IV and V of the parietal cortex. Apical dendrites
were pointed towards to the edge of the cortex. Since the
MNSCs were pre-treated with BrdU, the transplanted cells
have BrdU positive nuclei (red). Contrarily, the host, cell's
nuclei are counter stained with DAPI (blue). Many cells having BrdU positive nuclei are observed with bIII-tubulin
immunoreactivity in layer II and without bIII-tubulin immunoreactivity in layer III. (b, c) Higher magnification of the
parietal cortex in cortex layer IV: All the bIII-tubulin immunoreactive (green) positive cells show BrdU (red) positive
nuclei while many other host cell's nuclei are stained with
only DAPI (blue). MNSCs tend to have largernuclei than host
cells. (d) MNSCs migrated into the hippocampus and differ-
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photoreceptor cells, respectively. MeSCs of the invention
migrated into damaged area of the retinal tissue. A higher
magnification (b, x400) shows that these migrating MeSCs
also show cytosolic expression of op sin. (c) Typical in situ
hybridization histochemistry (xlOO) for human opsin gene
expression using human-specific opsin sequence riboprobes
(green). Incorporation ofhuman opsin positive cells to the rat
retinal tissue is observed.
FIG. 11 shows effect ofBrdU on restriction enzyme digestion of genomic DNA extracted from human MeSCs. BrdU
prevents methylation-sensitive restriction enzyme digestion
of DNA in a dose-dependent mamier, indicating that BrdU
treatment of MeSCs increased DNA methylation sites in the
genomic DNA.
FIG. 12 shows increased GFAP immunoreactivity in the
nucleus basalis magnocellularis (NBM) 4 weeks after saporin
lesion. Green: GFAP; Blue: DAPI.
FIG. 13 shows choline acetyltransferase (ChAT) immunoreactivity in BrdU positive cells in the lesion site indicating
replacement of lesioned cells by the transplanted cells of the
invention (a-c; Green: ChAT; Red: BrdU; Blue: DAPI) and
ChAT immunoreactivity in human nuclei positive cells in the
lesion site (d; Green: ChAT; Red: human nuclei; Blue: DAPI).
FIG. 14 shows human nuclei immunoreactivity-positive
cells that were observed in the lesion area. Red: human
nuclei; Blue: DAPI.
FIG. 15 shows GFAP and human nuclei immunoreactivity
in the lesion site. Green: GFAP; Red: human nuclei; Blue:
DAPI.
FIG. 16 shows expression ofreelin, a3-integrin and Dab-I
in the human MNSCs. (a) reelin immunoreactivity was
mainly detected in the neuronal like cells (green), while
GFAP positive cells (red) also possess reelin immunoreactivity. (b) a3-integrin (green) expresses specifically in the neuron-like cell, while Dab-I (red) express in most of the cells.
(c) Dab- I immunoreactivity (red) is highly localized in the
nuclei. (d) In side of the cluster ofMNSCs, we also detected
reelin immunoreactivity (green).
FIG. 17 shows an electron microscopic image showed that
a3-integrin immunoreactivity was localized on the membrane
of the cells.
FIG. 18 shows Western blot analysis of (a) reelin, (b)
a3-integrin and (c) DAB-1.
FIG. 19 shows reelin expression in embryonic stem cells.
Reelin immunoreactivity is showed in green and the nuclei
were stained with DAPI (blue).
FIG. 20 shows immunohistochemistry of control mouse
brain after human MNSC transplantation. (a) Human MNSCs
migrated into the cortex and differentiated into neurons as
indicated by bIII-tubulin positive cells (green). (b) Under
higher magnification, neuronally differentiated cells (green)
with BrdU positive nuclei (red) have morphologies typical of
pyramidal cells. (c) Human MNSCs migrated into the hippocampus and differentiated into bIII-tubulin positive cells
(green) with BrdU positive nuclei (red), having morphologies
typical of pyramidal cells in CAI pyramidal cell layer. (d) A
layer of GFAP positive human MNSCs (brown) were found in
the cortex. (e) Double-immunostaining revealed association
of the GFAP positive cells (red) with the bIII-tubulin positive
cells in the cortex.
FIG. 21 shows immunohistochemistry of reeler mouse
brain after human MNSC transplantation. (a) Few bIII-tubulin positive cells (green) were detected. (b) Under higher
magnification, we found one group ofBrdU positive cells on
the side of the injection. (c) Differentiation of human MNSCs
into bIII-tubulin positive cells in the hippocampus (green),
having different morphologies than the cells found in the

control animal in the CAI pyramidal cell layer. Though the
pyramidal cell layer is not particularly clear in this figure. (d)
A few GFAP positive human MNSCs (brown) were found in
the cortex. (e) A different morphology ofbIII-tubulin (green)
positive cells with BrdU positive nuclei (red) in the cortex. (f)
Chain migration of reelin (green) positive cells in the cortex.
FIG. 22 shows neuronal counts of BrdU-positive cells in
heterozygous (reeler (+/-), homozygous (reeler (-/-) and
wild-type mice in the hippocampus, olfactory bulb, and SVZ.
Significant reduction of the stem cell population was
observed in the hippocampus (p<0.001) and olfactory bulb
(p<0.01 ), but not in the SVZ of reeler (+/-) and reeler (-/-)
mice compared with wild-type mice by Fisher's Protected
LSD post hoc analysis after ANOVA.
FIG. 23 shows stem cells isolated from adult mice. (a)
During in vitro expansion, the stem cells formed a cluster of
multiple cells similar to those seen with NSCs. (b) The stem
cells differentiated into bIII-tubulin (green) and GFAP positive cells (red), indicating multipotency of these cells.
FIG. 24 shows that the human MNSCs were undergoing a
much greater degree of apoptotic cell death (yellow) during
differentiation in a serum-free unsupplemented medium (a)
when compared to serum differentiation (b ). The Fluorescein
Apoptosis Detection System (Promega, Madison, Wis.) was
used to assay the DNA fragmentation ofHNSCs at 3 DIV. All
the nuclei of HNSCs were counterstained by propidium
iodide (red) and the DNA fragmentation-positive cells were
stained in green.
FIG. 25 shows time-lapse video microscopy monitoring
the characteristics ofMNSC differentiation in cultures plated
in a serum-free unsupplemented medium at 2 DIV. The differentiating MNSCs (arrow) migrate away from the cluster of
cells (a). Interestingly, these cells are extending processes
onto nearby the morphologically shrunken, apparently apoptotic, cells (b ), followed by retraction of the processes (c ). The
processes appeared to be attached to the apoptotic cells (d),
which were drawn back into the cluster of cells (e ). The
response of differentiating NSCs to the apoptotic cells further
suggested that some component( s) of the apoptotic cells serve
as factors capable of influencing the physiological activity of
differentiating NSCs.
FIG. 26 shows that apoptotic cells in the serum-free differentiation conditions were APP immunopositive. All the
nuclei ofHNSCs were counter-stained by DAPI (a, blue). The
TUNEL signal (b, green) and immunoreactivity for APP recognized by the 22Cl I monoclonal antibody (which recognized the N-terminal end of APP) (c, red) are co-localized in
the cells of shrunken morphology in the serum-free differentiation condition (d).
FIG. 27 shows that treatment of human MNSCs in the
non-serum unsupplemented media with the 22Cl I monoclonal antibody recognizing the N-terminal end ofAPP dosedependently inhibited their differentiation. The panels show
typical morphology of human MNSCs when treated with
22Cl I (a; control, b; 125 µg/ml, c; 250 µg/ml, d; 500 µg/ml
22Cll) at 3DIV.
FIG. 28 shows that the treatment of the human MNSCs in
culture with the recombinant secreted type of amyloid precursor protein (sAPP) for 5 days dose-dependently increased
the differentiation of human MNSCs under serum-free
unsupplemented condition (a; control, b; 25 ng/ml, c; 50
ng/ml and d; 100 ng/ml).
FIG. 29 shows that the cell population of sAPP-treated
human MNSCs at 5 DIV in serum-free differentiation condition was characterized by double immunofluorescence staining with GFAP (red) and bIII-tubulin (green), which are
markers for astrocytes and neurons respectively. All nuclei
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were counter stained by DAPI (blue). The panels show typical
morphology and differentiation pattern of human MNSCs
treated with (a); control, (b ); 25 ng/ml, (c); 50 ng/ml and (d);
100 ng/ml of sAPP. At low doses of sAPP (e.g., 25 ng/ml),
increased glial (red) and neuronal (green) differentiation was
observed as compared to the control. With higher doses of
sAPP, many glialy differentiated human MNSCs (red) were
observed.
FIG. 30 shows the quantitative population analysis of the
each differentiation type. Cells immunostainedforGFAP and
bIII-tubulin were tallied versus total cell numbers of DAPIlabeled nuclei. All data values reported are expressed as mean
percentages (±S.E.M.). One Factor ANOVA followed by post
hoc analysis (Student- Newman-Keuls) was used to demonstrate statistically significant differences between experimental groups and control(*: p<0.01).
FIG. 31 shows that human MNSCs transfected with mammalian expression vectors containing genes for either wild
type APP (wtAPP) that were differentiated under serum-free
unsupplemented conditions displayed a significantly higher
level of glial differentiation as compared to human MNSCs
transfected with the vector alone at 5DIV. Pictures show
double immunofluorescence staining with GFAP (red) and
bIII-tubulin (green), which are markers for astrocytes and
neurons respectively. All nuclei were counter stained by
DAPI (blue).
FIG. 32 shows thatthehumanMNSCs transplanted to APP
knockout mouse brain show less migration and differentiation as compared to cells transplanted into wild type control
mice. Human MNSCs were treated with BrdU before the
unilateral ventricle injection to aid in the discrimination from
host cells. Brain tissues were immunoblotted for bIII-tubulin,
GFAP, and BrdU 4 weeks post-injection. In the wild type
mice, the immunopositive cells for BrdU (red) and bIII-tubulin (green) distributed bilaterally in the singular and parietal
cortexes (a) and pyramidal layer of the hippocampus (c),
indicating neuronal differentiation of transplanted human
MNSCs. The human MNSCs also differentiated into GFAPimmunopositive cells (red) that localized with the bIII tubulin
(green) stained neuronal fibers of layer III in the cortex (e ).
The differentiation and distribution patterns of the transplanted human MNSCs were similar to what we found in our
previous transplantation study with rats. In the APP knockout
mice, those bIII-tubulin positive cells (green) with BrdU positive nuclei (red), derived from the transplanted human
MNSCs, that were seen in the cortex were scarcely distributed
and lacked apical dendrites (b ). In the hippocampus, bIIItubulin (green) and BrdU (red) immunopositive cells had
quite similar distribution and structure to the cells found in the
wild type mice (d,f).
FIG. 33 shows a comparison of endogenous NSC populations in APP knockout and wild-type mice (xlOO). BrdU
incorporated into the nuclei of proliferating cells was
detected by fluorescent immunohistochemistry (red), and all
the nuclei were counter-stained with DAPI (blue). The upper
panels show a dramatically decreased population of stem
cells in the hippocampus of APP knockout mouse (a) compared with wild-type mouse (b). The lower panels show a
similar population of stem cells in the subventricular zone
(SVZ) of APP-knockout mice (c) compared with wild-type
mice (d).

larly more developmentally potent cells that can be administered to an animal in need thereof.
As disclosed in further detail herein, the inventive methods
provide for culturing less developmentally potent cells
obtained, inter alia, from somatic tissue sources, and producing more developmentally potent, cells therefrom. In one
aspect, this effect is achieved by culturing the less developmentally potent cells in the presence of a substituted deoxynucleotide or deoxynucleoside compound. Exemplary substituted deoxynucleotide or deoxynucleoside compounds as
provided by the invention include but are not limited to halogen-substituted (halo-substituted) deoxynucleotides or
deoxynucleosides, such as, for example, bromodeoxyuridine,
iododeoxyuridine, bromodeoxyguanosine, iododeoxycytosine as well as alkyl-substituted species such as, for
example, methyldeoxythymidine. A most preferred species is
bromodeoxyuridine (BrdU). BrdU is a thymidine analog that
was originally produced for chemotherapy. It is known to
regulate gene expression and cellular differentiation of some
cell types. Since BrdU and other substituted deoxynucleotide
or deoxynucleoside compounds, are incorporated into the
nuclei of proliferating cells and are easy to detect by immunostaining, it has been used for detecting proliferating cells,
such as stem cells; however, its biological effects on stem
cells has not been appreciated, understood or disclosed in the
art.
While adult stem cells continue to possess some multipotency, adult stem cells are limited by their tissue-specific
character. As an example, human NSCs spontaneously differentiate into brain cells under basal media conditions, but
MeSCs are essentially unable to spontaneously differentiate
into neural cells without the addition of certain factors; in the
context of the invention, such cells are less developmentally
potent than cells that could differentiate into cells of two or
more different lineages. These results indicate that each kind
of tissue-specific stem cell contains specific information that
allows it to become a special type of cell, i.e., they are partially committed to become a particular type of cell in a
tissue-specific manner (i.e., less developmentally potent). To
overcome this barrier of stem cell lineage and make cells that
are more developmentally potent, alterations to the cells and
their environment are necessary. The invention relates to
methods of making more developmentally potent cells from
less developmentally potent cells, as well as methods of treatment and use of the more developmentally potent cells, and
the more developmentally potent cells themselves. As an
example, the invention relates to the treatment of easily isolated and abundant stem cells like mesenchymal stem cells
(i.e., a less developmentally potent cell) such that they are no
longer constrained to differentiate into only mesenchymallineage cells such as osteocytes and chrondrocytes, among
others. Treated according to the invention, the less developmentally potent mesenchymal stem cell becomes a more
developmentally potent cell capable of differentiation into,
for example, neural-lineage cells. The present invention also
enables the use of autologous transplantation, which eliminates possibility of an immune reaction against a transplant of
the more developmentally potent cells of the invention. For
example, a patient's mesenchymal stem cells could be isolated, treated according to the methods of the invention, and
transplanted back into the same patient to differentiate in a
tissue-specific mamier regardless the transplantation site, be
it brain, eye, muscle, etc. Thus, the present invention provides
a means to treat neurological and corporal deficits without the
problems associated withheterologous transplants from adult
or fetal sources.
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As used herein, the terms "multipotent neural stem cells
(MNSCs)," "neural stem cells (NSCs)" and "neural progenitor cells (NPCs)" refer to undifferentiated, multipotent cells
of the CNS. Such terms are commonly used in the scientific
literature. MNSCs can differentiate into tissue-specific cell
types, for example astrocytes, oligodendrocytes, and neurons
when transplanted in the brain. MNSCs of the invention are
distinguished from natural MNSCs by their adaptation for
proliferation, migration and differentiation in mammalian
host tissue when introduced thereto.
As used herein, a "less developmentally potent cell" is a
cell that is capable oflimited multi-lineage differentiation or
capable of single-lineage, tissue-specific differentiation, for
example, an untreated riesenchymal stem cell can differentiate into, inter alia, osteocytes and chrondrocytes, i.e., cells of
mesenchymal lineage, but has only limited ability to differentiate into cells of other lineages (e.g., neural lineage.).
As used herein, a "more developmentally potent cell" is a
cell that is readily capable of differentiating into a greater
variety of cell types than its corresponding less developmentally potent cell. For example, a mesenchymal stem cell can
readily differentiate into osteocytes and chrondrocytes but
has only limited ability to differentiate into neural or retinal
lineage cells (i.e., it is a less developmentally potent cell in
this context). Mesenchymal stem cells treated according to
the methods of the invention become more developmentally
potent because they can readily differentiate into, for
example, mesenchymal-lineage and neural-lineage cell
types; the plasticity of the cells is increased when treated
according to the methods of the invention.
One or more of the more developmentally potent cells of
the invention can propagate as separate cells and can also
form a cluster of two or more cells. The clusters can comprise
the progeny of a single more developmentally potent cell or
clusters of primary cells.
As used herein, the terms "effective amount" and "therapeutically effective amount" each refer to the amount of
reagent used to support the desired activity. In the case of
more developmentally potent cells prepared and delivered
according to the invention, an effective amount is an amount
necessary to support an observable level of one or more
biological activities of MSC as set forth herein. Regarding
substituted deoxynucleotide or deoxynucleoside compounds,
an effective amount can be between about 10 nanomolar and
100 micromolar, or more preferably between about 2 and 50
micromolar, or even more preferably about 10 micromolar.
Regarding the method of making a retinal cell from the cells
of the invention, an effective amount ofTGF-b3, CNTF and
IGF can be between about 1 ng/ml to 1 ug/ml, or more
preferably between about 5 ng/ml to 500 ng/ml, or even more
preferably between about 10 ng/ml to 100 ng/ml, or even
more preferably about 50 ng/ml.
An "effective period" as used herein refers to the time
period necessary for the reagents and cells of the invention to
accomplish their specified activities. For example, less developmentally potent cells can be contacted with a substituted
deoxynucleotide or deoxynucleoside compound for an effective period to make them more developmentally potent. An
effective period for contact with a substituted deoxynucleotide or deoxynucleoside compound, as referred to herein,
can be between 1 to 10 days, or more preferably between
about 1 to 5 days, or even more preferably between about 2 to
3 days. Further, cells of the invention can be contacted before
or during differentiation with TGF-b3, CNTF, IGF, or combinations thereof, for an effective period to make them
capable of differentiating into retinal cells. An effective
period for TGF-b3, CNTF and IGF contact, as referred to

herein, can be between to 10 days, or more preferably
between about 1 to 7 days, or even more preferably between
about 2 to 5 days.
The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or
more formulation materials suitable for accomplishing or
enhancing the successful delivery of the pharmaceutical composition of more developmentally potent cells prepared and
delivered according to the invention.
As used herein, "ameliorating the effects caused by age,
physical and biological trauma and degenerative disease" and
the like refers to the diminution of the detrimental effects of
damaged or degenerated tissue due to the use or administration of an effective amount of the more developmentally
potent cells of the invention, or pharmaceutical preparations
thereof, to the affected, damaged or degenerated tissue,
wherein the stem cells can differentiate in a manner appropriate for the host tissue and enable the replacement of damaged cells, repair of damages tissue and reduction of structural or functional loss. For example, the neurological effects
of events, diseases or processes that result in the loss of some
degree of brain function or proper brain function. Such amelioration is affected through the administration to the animal
of an effective amount of the more developmentally potent
cells or pharmaceutical compositions thereof of the invention.
The invention also provides pharmaceutical compositions
of the more developmentally potent cells of the invention and
methods of delivery into the brain and other tissues thereof.
The invention also provides methods of abating or remedying
the effects of brain or other tissue disease or dysfunction
caused by the loss of, or loss of appropriate, brain or other
tissue function due to age, physical or biological trauma or
neurodegenerative disease.
Cells can be obtained in many ways and from many tissues,
for example, from donor tissue by dissociation of individual
cells from the connecting extracellular matrix of the tissue or
from commercial sources ofNSCs (e.g., Bio Whittaker, Walkersville, Md., CC-25 99 ). For certain neural stem cell embodiments of the more developmentally potent cells of the invention, tissue from brain is removed using sterile procedures,
and the cells are dissociated using any method known in the
art including treatment with enzymes such as trypsin, collagenase and the like, or by using physical methods of dissociation such as mincing or treatment with a blunt instrument.
Dissociation of neural cells, and other multi potent stem cells,
can be carried out in tissue culture medium; in a preferred
embodiment, the medium for dissociation of juvenile and
adult cells is low calcium artificial cerebral spinal fluid
(aCSF) having a formula identical to aCSF (124 mM NaCl, 5
mM KC!, 1.3 mM MgCl 2 , 2 mM CaCl 2 , 26 mM NaHC0 3 ,
and 10 mM D-glucose) except that MgCl 2 is present at a
concentration of3.2 mM and CaCl 2 at a concentration of0.1
mM. Dissociated cells are centrifuged at low speed, between
200 and 2000 rpm, usually between 400 and 800 rpm, the
suspension medium is aspirated, and the cells are then resuspended in culture medium. Suspension cultures are preferred
if large numbers of undifferentiated stem cell progeny are
desired. Cell suspensions are seeded in any receptacle
capable of sustaining cells, preferably uncoated flask or a
flask that has been treated to repel the cells, culture plates or
roller bottles that inhibit contact-dependent stem cell differentiation.
While isolation from brain tissue is feasible, mesenchymal
stem cells from bone is a particularly good source of cells for
use in generating more developmentally potent cells for use in
the invention because isolation techniques are well estab-
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lished in the art (having been used for decades in immune
disorder bone marrow transplants), and such techniques can
be performed autologously. The patient's own mesenchymal
stem cells can be isolated, treated according to the invention
and readministered where necessary. In contrast, autologous
transplants using a neural cell source is not particularly feasible.
Growth of more developmentally potent cells under the
above culture conditions induces or permits these cells to
form undifferentiated clusters of two or more cells (shown in
FIG. 1). These clusters are optimally grown at a density of
approximately 50 per T75 flask in 20 mL of the growth
medium consisting of, for example, DMEM/HAMS F12 (at
about 3: 1; Gibco, BRL, Burlington, ON), supplemented with
an antibiotic-antimycotic mixture (1: 100, penicillin G, streptomycin sulfate, amphotericin B; Gibco ), B27 (1:50,
GIBCO), human recombinant FGF-2 and EGF (20 ng/ml
each, R&D Systems, Minneapolis, Minn.) and heparin (5
µg/mL, Sigma, St. Louis, Mo.). The cultures are kept in a C0 2
incubator (about 5% C0 2 ) at 37° C. To facilitate optimal
growth conditions, any clusters of two or more cells are
sectioned into quarters approximately every 14 days and fed
by replacing 50% of the medium approximately every 4-5
days. These conditions permit rapid and continual growth of
NSCs, as well as the more or less developmentally potent
cells of the invention, that can be expanded indefinitely while
retaining their multipotent character. As with most eukaryotic
cells, conditions for culturing should be as close as possible to
physiological conditions. The pH of the culture medium
should be close to physiological pH, preferably between pH
6-8, more preferably between about pH 7 to 7 .8, with pH 7.4
being most preferred. Physiological temperatures range
between about 30° C. to 40° C. Cells are preferably cultured
at temperatures between about 32° C. to about 38° C., and
more preferably between about 35° C. to about 37° C. Neural
stem cells (NSCs) prepared and maintained as disclosed
herein continue to exhibit multipotent character after more
than three years of serum-free propagation. If in vitro differentiation is desired, the cells can be rep lated in culture dishes
in, for example, serum-free basal medium Eagle (BME),
which contains Earle's salt and L-glutamine. The cells can be
cultured for about 5 days in the absence of FGF-2, EGF or
other extrinsic differentiation factors. When induced to differentiate in this way, these cultured NSCs exhibit characteristic morphologies of neurons or astrocytes when immunohistochemically stained with b-III tubulin (a neuronal cell
marker) or glial fibrillary acidic protein (GFAP, an astrocyte
marker).
As disclosed above, the stem cell culture medium as used in
the invention is preferably supplemented with at least one
proliferation-inducing growth factor. A growth factor, as
defined herein, refers to a protein, peptide or other molecule
having a growth, proliferative, or trophic effect on the more or
more developmentally potent cells and/or more or more
developmentally potent cell progeny of the invention. Growth
factors that are used for inducing proliferation include any
trophic factor that allows more or more developmentally
potent cells to proliferate, including any molecule that binds
to a receptor on the surface of the cell to exert a trophic, or
growth-inducing effect on the cell. Exemplary proliferationinducing growth factors include epidermal growth factor
(EGF), insulin-like growth factor (IGF), ciliary neurotrophic
factor (CNTF), amphiregulin, acidic fibroblast growth factor
(aFGF or FGF-1), basic fibroblast growth factor (bFGF or
FGF-2), and combinations thereof. Preferred proliferationinducing growth factors include EGF and FGF or a combination thereof. Growth factors are usually added to the culture

medium at concentrations of between about 1 fg/mL to 1
mg/mL. Concentrations between about 1 to 100 ng/mL are
usually sufficient. Simple titration experiments routine in the
art are used to determine the optimal concentration of a particular growth factor for a particular cell culture.
Cells of the invention that are proliferated in serum-free
media should be grown in the presence ofa substituted deoxynucleotide or deoxynucleoside compounds such as, for
example, halogenated-deoxynucleosides like bromodeoxyuridine (BrdU) or iododeoxyguanosine (IrdG), alkyl-substituted examples such as methyldeoxyguanosine prior to transplantation into a host. The pre-transplant growth medium
comprises the components of the long-term propagation
media, but also contains an effective amount of substituted
deoxynucleotide or deoxynucleosides for use for an effective
period. More developmentally potent cells prepared according to the methods of the invention are conditioned or adapted
to proliferate, migrate and differentiate properly in the brain
when transplanted into host tissue.
Cellular preparations and pharmaceutical compositions of
the more developmentally potent cells of the invention are
also provided herein. Pharmaceutical compositions optimally
comprise a therapeutically effective amount of more developmentally potent cells in admixture with a pharmaceutically
or physiologically acceptable formulation agent selected for
suitability with the mode of administration. Acceptable formulation materials preferably are nontoxic to the more developmentally potent cells and the recipients at the dosages and
concentrations employed.
The cellular preparations and pharmaceutical compositions of the invention may contain formulation materials for
modifying, maintaining, or preserving, for example, pH,
osmolarity, viscosity, clarity, color, isotonicity, odor, sterility,
stability, rate of dissolution or release, adsorption, or penetration of the composition, as well as proliferation, migration
and differentiation capacity of the more developmentally
potent cells of the invention. Suitable formulation materials
include, but are not limited to, amino acids (such as glycine,
glutamine, asparagine, arginine, or lysine), antimicrobial
compounds, antioxidants (such as ascorbic acid, sodium
sulfite, or sodium hydrogen-sulfite), buffers (such as borate,
bicarbonate, Tris-HCl, citrates, phosphates, or other organic
acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid
(EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, betacyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, marmose, or dextrins ), proteins
(such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents,
hydrophilic polymers (such as polyvinylpyrrolidone), low
molecular weight polypeptides, salt-forming counterions
(such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic
acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such
as marmitol or sorbitol), suspending agents, surfactants or
wetting agents (such as pluronics; PEG; sorbitan esters;
polysorbates such as polysorbate 20 or polysorbate 80; triton;
trimethamine; lecithin; cholesterol or tyloxapal), stability
enhancing agents (such as sucrose or sorbitol), tonicity
enhancing agents (such as alkali metal halides-preferably
sodium or potassium chloride--or mannitol sorbitol), delivery vehicles, diluents, excipients and/ or pharmaceutical adju-
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vants. See REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing
Company 1990).
The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For
example, a suitable vehicle or carrier for injection may be
water, physiological saline solution, or artificial cerebrospinal fluid. Optimal pharmaceutical compositions will be determined by a skilled artisan depending upon, for example, the
intended route of administration, delivery format, desired
dosage and recipient tissue. See, e.g., REMINGTON'S
PHARMACEUTICAL SCIENCES, supra. Such compositions may influence the physical state, stability, and effectiveness of the MNSC composition.
The invention provides methods of delivery and transplantation of the more developmentally potent cells of the invention to ameliorate the effects of age, physical and biological
trauma and degenerative disease on the brain or central nervous system of an animal, as well as other tissues such as, for
example, retinal tissue. It is well recognized in the art that
transplantation of tissue into the CNS offers the potential for
treatment of neurodegenerative disorders and CNS damage
due to injury. Transplantation of new cells into the damaged
CNS has the potential to repair damaged circuitries and provide neurotransmitters thereby restoring neurological function. It is also recognized in the art that transplantation into
other tissue, such as eye tissue, offers the potential for treatment of degenerative disorders and tissue damage due to
injury. As disclosed herein, the invention provides methods
for generating more developmentally potent cells adapted for
proliferation, migration and differentiation in mammalian
tissue when introduced thereto. The use of more developmentally potent cells in the treatment of neurological disorders
and CNS damage, as well as the use of more developmentally
potent cells in the treatment of other tissue damage or degeneration, can be demonstrated by the use of established animal
models known in the art.
More developmentally potent cells of the invention can be
administered to an animal with abnormal or degenerative
symptoms obtained in any manner, including those obtained
as a result of age, physical or biological trauma, or neurodegenerative disease and the like, or animal models created by
man using recombinant genetic techniques, such as transgenic and "gene knockout" animals.
Recipients of the more developmentally potent cells of the
invention can be immunosuppressed, either through the use of
immunosuppressive drugs such as cyclosporin, or through
local immunosuppression strategies employing locally
applied immunosuppressants, but such immunosuppression
need not necessarily be a prerequisite in certain immunoprivileged tissues such as, for example, brain and eye tissues. In
certain embodiments, the delivery method of the invention
can cause less localized tissue damage to the site of cell
damage or malfunction than existing methods of delivery.
More developmentally potent cells of the invention can be
prepared from the recipient's own tissue. In such instances,
the progeny of the more developmentally potent cells can be
generated from dissociated or isolated tissue and proliferated
in vitro using the methods described herein. In the case of
mesenchymal stem cells (MeSCs ), progeny can be generated
from MeSCs isolated from, for example, bone marrow. Upon
suitable expansion of cell numbers, the stem cells of the
invention can be harvested and readied for administration into
the recipient's affected tissue.
There are significant differences in the method of delivery
to the brain of the more developmentally potent cells compared to the prior art. One exemplary difference is as follows:

the more developmentally potent cells of the invention are
transplanted intraventricularly. Further, while the transplantation of one or more separate more developmentally potent
cells is efficacious, the more developmentally potent cells of
the invention are preferably transplanted in the form of clusters of two or more cells via a surgical procedure or injection
using a syringe large enough to leave the clusters substantially intact. The results disclosed in the Examples below
indicate that ventricular delivery of more developmentally
potent cells of the invention in the form of a cluster of two or
more cells can result in migration to the area of damage in the
brain and proper neuronal differentiation. Another benefit of
intraventricular injection is less tissue destruction, resulting
in less localized recruitment of immune cells by the host. This
is evidenced by the lack of ventricular distortion, tumor formation, and increased host astrocyte staining without any
immunosuppression.
The method of delivery of the more developmentally
potent cells of the invention to the brain can be essentially
duplicated for other immunoprivileged tissue such as, for
example, the eye. Delivery of one or more separate or two or
more of the more developmentally potent cells in the form of
a cluster via injection using a syringe large enough to leave
the any cluster of two or more cells that is present substantially intact can result in migration to the area of damage in the
eye and proper tissue-specific differentiation.
There are examples in the art of intra-tissue injection
(brain) of dissociated and partially differentiated NSCs (see,
e.g., Benninger et al., 2000, Brain Pathol. 10: 330-341;
Blakemore et al., 2000, Cell Transplant. 9: 289-294; Rosser et
al., 2000, Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000,
Mal. Cell. Neurosci. 16: 1-13). Further, the dissociation of
NSC neurospheres is known to cause immediate senescence
of NSCs and increase the vulnerability of NSCs in culture.
See, e.g., Svendsen et al., 1998, J. Neurosci. Methods 85:
141-15 2. Some aspects of the instant invention preferentially
employ injection of clusters of two or more cells, but the more
developmentally potent cells of the invention appear to
migrate and differentiate appropriately when transplanted in
non-cluster from as well. As provided by this invention, intraventricular transplantation provides an alternative route to the
site-specific injection disclosed in the prior art. Using intraventricular transplantation, grafted cells can gain access to
various structures by the flow of CSF, and transplantation of
more developmentally potent cells of the invention in cluster
form can act to prevent premature differentiation at inappropriate anatomical sites in the brain and central nervous system. Regarding the eye, intraocular administration of clusters
of two or more cells, for example into the vitreous fluid,
allows the more developmentally potent cells of the invention
to migrate to the area of degeneration or injury and differentiate appropriately.
Delivery of more developmentally potent cells of the
invention into other, non-immunoprivileged tissues can also
be carried out, particularly when the more developmentally
potent cells are autologous to the recipient.
Functional integration of the graft into the host's neural
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions, including but not limited to tests for endocrine, motor, cognitive and sensory functions. Useful motor tests include tests that quantitate rotational movement away from the degenerated side of the brain,
and tests that quantitate slowness of movement, balance,
coordination, akinesia or lack of movement, rigidity and
tremors. Cognitive tests include tests of the ability to perform
everyday tasks, as well as various memory tests, including
maze performance such as the Morris water maze perfor-
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mance. For example, using the cells and methods of the
invention, more developmentally potent cells injected into the
ventricle of 24 month-old rats after in vitro expansion displayed extensive and positional incorporation into the aged
host brain with improvement of cognitive score (FIG. 2), as
assessed by the Morris water maze after 4 weeks of the
transplantation. Results of the experiments disclosed herein
indicate that the aged brain is capable of providing the necessary environment for more developmentally potent cells of
the invention to retain their multipotent status and demonstrate the potential for neuroreplacement therapies in age
associated neurodegenerative disease.
Functional integration of the graft into the host's other
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions specific to the injured or
degenerated tissue, for example improvement in sight for
transplantation of stem cells of the invention to the eye.
Regarding the eye, using the cells and methods of the invention, more developmentally potent cells of the invention
injected into the vitreous cavity of rat eyes after in vitro
expansion displayed extensive and positional incorporation
into the host eye tissue (FIG. 3) 4 weeks post-transplantation.
Results of the experiments disclosed herein indicate that the
eye, as with the brain, is capable of providing the necessary
environment for the more developmentally potent cells of the
invention to differentiate in a tissue-specific manner, and thus
demonstrate the potential for replacement therapies in injury
or degeneration-associated tissue damage.
Without being restricted to any particular theory for the
mechanism of action of the cells and methods of the invention, there are at least two explanations for the beneficial
effects of more developmentally potent cell transplantation to
cognitive function of the host brain as well as the beneficial
effects of more developmentally potent cell transplantation in
other tissues. One is replacement or augmentation. Neuronal
circuits can be replaced or augmented by the more developmentally potent cell-derived neurons. In other tissues, cells
and cell structures can also be replaced or augmented by more
developmentally potent cell-derived cells appropriate for that
tissue. An alternative explanation is the trophic action of
factors released from the transplanted more developmentally
potent cells. Morphological analysis of rat brains transplanted with the more developmentally potent cells as disclosed herein showed extensive incorporation of the more
developmentally potent cells and massive growth of neuronal
fibers in the host brain area related to spatial memory task
(FIGS. 4 and 5); however, the more developmentally potent
cells may still migrate toward the damaged neurons and rescue them by the production of neurotrophic factors. Synergy
between these two explanations may also exist.
As assessed by the Morris water maze test, improvement in
spatial memory of more developmentally potent cell-transplanted animals was accompanied by incorporation of the
more developmentally potent cells into the brain areas known
to be related to spatial memory. The post-transplant morphology of rat brain tissue indicates that functional association of
the transplanted cells to the host brain occurs. Immunohistochemical analysis revealed that the bIII-tubulin-positive
donor-derived cells found in the cerebral cortex are characterized by having dendrites pointing to the edge of the cortex
whereas in the hippocampus, donor-derived neurons exhibited morphologies with multiple processes and branches.
These differential morphologies of the transplanted more
developmentally potent cells in different brain regions indicate that site-specific differentiation of the more developmentally potent cells occurs according to various factors present
in each brain region.

Strong astrocyte staining was also found in the frontal
cortex layer 3 and CA2 region of hippocampus in transplanted rat brains, areas where astrocytes are not normally
present in the animal. The migration of the more developmentally potent cells to the CA2 is of particular interest because
CA2 pyramidal neurons highly express bFGF, and the expression of bFGF is up-regulated by entorhinal cortex lesions
(see, e.g., Eckenstein et al., 1994, Biochem. Pharmacol. 47:
103-110; Gonzalez et al., 1995, Brain Res. 701: 201-226;
Williams et al., 1996, J. Comp. Neural. 370: 147-158). CA2
pyramidal neurons in the host brain can express bFGF as a
response to a reduction of synaptic transmission, an event that
can occur during aging. Subsequently, this expressed bFGF
can act as a signal for the transplanted more developmentally
potent cells to respond, migrate or proliferate under the influence ofbFGF produced in the host brain after the transplantation.
The regions rich in astrocyte staining in transplanted rat
brains are the same regions where extensively stained neuronal fibers were identified (FIGS. 4a, 4d and 4e). During
development, glial cells have many complex functions, such
as neuronal and axonal guidance and production of trophic
factors (see, e.g., Pundt et al., 1995, Brain Res. 695: 25-36).
This overlapping distribution of glial and neuronal fibers
strongly suggests that this interaction plays a pivotal role in
survival, migration, and differentiation of transplanted more
developmentally potent cells.
Immunohistochemistry of transplanted rat brains reveals a
symmetrical distribution of neurons and astrocytes at both
sides of the host brain, indicating that the progeny of these
more developmentally potent cells can migrate. Although
astrocytes have been shown to migrate over long distances
following transplantation (see, e.g., Blakemore et al., 1991,
Trends Neurosci. 14: 323-327; Hatton et al., 1992, Glia 5:
251-258; Lundberg et al., 1996, Exp. Neural. 139: 39-53),
there is experimental evidence showing that neurons do not
migrate as widely as glial cells (see, e.g., Fricker et al., 1999,
J. Neurosci. 19: 5990-6005). As disclosed herein, neuronal
precursors derived from the more developmentally potent
cells of the invention possess similar migratory capacity to
astrocyte precursors.
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Bioreactor
The use ofbiocatalyst for the production of useful products
has been a part of man's history for thousands of years. Until
this century the production of useful products from biocatalysts was performed in batch-type reactors (fermenters).
Numerous newer, more efficient methods utilizing bioreactors are used to regulate important growth parameters such as,
for example, pH, oxygen, sterility, nutrition. The basic economics behind biological production are two-fold: producing
a product with greater value than the raw material it was
derived from and producing a product that cannot be economically made in any other way, in both cases for the purpose of satisfying market demand.
For bulk biochemical production, such as beer, the principle costs are in the initial raw materials and initial capital
costs for the production facility since millions of gallons of
beer must be produced to obtain a reasonable return on the
investment. It should also be noted that yields of these products are some of the highest of any biologically derived products.
At the other extreme is high-value biochemical production,
such as monoclonal antibody, whose largest expense is in the
downstream processing of the product. This can occur
because the difficulty of obtaining certain biological starting
materials as well as other reasons such as federal regulations
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stipulating the purity of the final product if it is to be used in
vivo. In this situation, however, the very small amount of
product produced and the difficulty in performing the production requires that the final product be sold at many orders of
magnitude higher than the bulk biochemical for the same
basic quantity. In certain circumstances, the cost of obtaining
critical materials for biochemical production can be so prohibitive that such production is not economically feasible.
Further, some materials are simply not available at any cost,
so methods enabling the conversion of more easily obtained
(orobtainable at all) materials into that critical material can be
extremely valuable.
The methods of the invention make possible the conversion
of easily obtainable less developmentally potent cells, for
example MeSCs, to more developmentally potent cells, cells
that can be subsequently differentiated in vitro to the desired,
and possibly difficult to obtain, cell type for use as a bioreactor for the production of proteins or products specific to the
differentiated cell. Differentiation can be induced through
exposure of the cells of the invention to growth factors and
supplements known in the art to be important in differentiation of the desired cell type. As described elsewhere herein,
more developmentally potent cells of the invention ofMeSC
origin were induced to differentiate in vitro to cells of retinal
origin through exposure to TGF-b3, CNTF, or IGF-1. Further,
using the growth conditions described herein, the more and
less developmentally potent cells themselves can be propagated long terms and used as bioreactors for production of
proteins or products specific to those cells. The ability to
easily isolate and propagate a potentially unlimited population of more developmentally potent cells that have the capacity to terminally differentiate into a desired cell type enables
the biochemical production of heretofore unavailable or prohibitively expensive cellular products.
The methods of the invention also make personalized drug
screening much more feasible, both technically and monetarily. Easily obtained less developmentally potent cells
such as MeSCs, can be treated according to the methods of the
invention and induced to a cell type appropriate for the testing
of a particular drug. For example, neurally differentiated cells
have been used as an experimental system for drugs that act
on the brain. While NSCs can be commercially obtained, they
are not specific to any particular person and are thus useless
for personalized drug efficacy testing. Using the methods of
the invention, a person's less developmentally potent cells,
for example MeSCs isolated using minimally invasive methods well established in the art, can be converted into more
developmentally potent cells that can be differentiated into,
for example, cells of neural origin and utilized for testing.
Such methods can be used to determine the effect of drugs on,
for example, expression levels of particular genes induced by
particular drugs for a particular patient. Such information can
be critical in determining appropriate or inappropriate reactions, at a biochemical level, to a drug, which can be critical
information for any drug with the potential for undesired, and
often dangerous or fatal, effects.
As the more developmentally potent cells of the invention
can mimic neural stem cells in many regards, relevant information pertaining to neural stem cells is presented, followed
by information pertaining to mesenchymal and retinal stem
cells. One of skill in the art will readily recognize the methods
of the invention are not limited to these three types of stem
cells and instead extend to cover all cell types not yet terminally differentiated.

Neural-Related
Due to the generally low proliferation rate of manimalian
NSCs, there is a correlation between advancing age and
impaired brain function even in the absence of specific neurodegenerative disease or physical or biological brain trauma.
The invention provides methods for counteracting impaired
brain function due to advancing age through the addition of
more developmentally potent cells capable of proliferation,
migration and differentiation in mammalian brain when
introduced thereto.
Physical trauma and biological trauma are additional
causes of impaired or improper brain function. The term
"physical trauma" denotes brain cell damage due to external
sources such as blunt head trauma, severe concussion and the
like. Such physical trauma can be localized or general
depending on the source and severity of the trauma. The term
"biological trauma" denotes any acute brain injury that has its
origin in a biological process, for example, stroke, aneurysm,
epilepsy, brain tumor, hypoxia and the like.
Another source of impaired or improper brain function is
neurodegenerative disease. In recent years neurodegenerative
disease has become an important concern due to an expanding
elderly population that is at greatest risk for these disorders.
Neurodegenerative diseases include, but are not limited
Alzheimer's disease, amyotrophic lateral sclerosis (ALS),
Parkinson's disease, Pick's disease, Huntington's disease,
progressive supranuclear palsy, corticobasal degeneration,
Parkinson-ALS-dementia complex, Gerstmann-StrausslerScheinker syndrome, Hallervorden-Spatz disease, Kufs' disease, Wilson's disease, multiple sclerosis (MS), late-onset
metachromatic leukodystrophy and adrenoleukodystrophy.
The effects of these diseases can be counteracted by administration of the more developmentally potent cells of the
invention.
There is a variety of organic brain diseases that impair
motor or cognitive function. Degeneration in the basal ganglia can lead to diseases with cognitive and motor symptoms,
depending on the exact location of the degeneration. Motor
deficits are a common result of degeneration in the basal
ganglia. Huntington's Chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary
jerking movements in the host. Degeneration of a small
region called the subthalamic nucleus is associated with violent flinging movements of the extremities in a condition
called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing
movements or athetosis. In Parkinson's disease, degeneration
is seen in another area of the basal ganglia, the substantia
nigra par compacta. This area normally sends dopaminergic
connections to the dorsal striatum, which are important in
regulating movement. Therapy for Parkinson's disease has
centered upon restoring dopaminergic activity to this circuit,
which can be accomplished by transplantation of more developmentally potent cells to this region of the brain according to
the instant invention.
In Alzheimer's disease, another neurodegenerative disease, there is substantial cellular degeneration of the forebrain
and cerebral cortex. Further, a localized area of the basal
ganglia, the nucleus basalis of Meynert, appears to be selectively degenerated. This nucleus normally sends cholinergic
projections to the cerebral cortex, which are thought to participate in cognitive functions including memory.

10

15

20

25

30

35

40

45

50

55

60

65

Mesenchymal Related
Although adult stem cells continue to possess some multipotency, cell types produced from adult stem cells are limited
by their tissue-specific character. For example, human NSCs
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spontaneously differentiate into brain cells under basal media
conditions, but MeSCs are essentially unable to readily and
spontaneously differentiate into neural cells without the addition of certain factors; in the context of the invention, such
cells are less developmentally potent than cells that could
differentiate into cells of two or more different lineages.
These results indicate that each kind of tissue-specific stem
cell contains specific information that allows it to become a
special type of cell, i.e., they are partially committed to
become a particular type of cell in a tissue-specific manner
(i.e., less developmentally potent). To overcome this barrier
of stem cell lineage and make cells that are more developmentally potent, alterations to the cells and their environment
are necessary. However, the exact regulation mechanisms of
tissue-specific stem cell fate decisions remain unclear. This
knowledge base gap poses an important problem, because
although MeSCs are rather easy to isolate from bone marrow
and to proliferate in culture, they are essentially unable to
readily differentiate into NSCs or other non-mesenchymallineage cells. Although the potential therapeutic use of
MeSCs in the central nervous system has been discussed,
technologies to induce neural lineage in MeSCs had not been
fully established prior to the instant invention.
MeSCs of the invention can serve as an alternative to NSCs
for potential therapeutic use utilizing the methods of the
invention, which exploit the capacity of substituted deoxynucleotide or deoxynucleoside species, such as BrdU, to
prime the MeSCs, i.e., remove them from their restricted
mesenchymal differentiation path to the neural stem cell-like
(or other lineage) differentiation path. MeSCs were successfully differentiated into neurons and glia in vitro and in vivo
using the substituted deoxynucleotide or deoxynucleoside
pretreatment of the invention. Thus, MeSCs of the invention
can serve as an alternative to NSCs for potential therapeutic
use in neuroreplacement utilizing the methods of the invention.
These cells are important in the neuroreplacement therapy
field because their production permits autologous transplantation. Stem cells can be isolated from the patient, expanded
in vitro, genetically modified if desired or necessary and
transplanted back to the same patient. Since neural stem cells
can be differentiated into most peripheral tissue cells, the
invention is not only useful to neuroreplacement but to other
kinds of tissue regeneration or replacement as well. In addition, since the cells originate from the patient, there are no
ethical barriers or immunorejection issues with which to contend.

have provided evidence that birds and adult mammals also
possess a zone of cells at the retinal margin analogous to the
ciliary marginal zone of cold-blooded vertebrates. These retinal stem cells are reported not only to generate photoreceptor
and other retinal cells in vitro, but also to differentiate into
retinal cells following transplantation into the retinal area.
Although these results indicate the possibility of retinal
regeneration therapy, an alternative source of stem cells is
required for clinical applications because the number of retinal stem cells is limited.
Neural stem cells have been isolated from embryonic and
adult mammalian brains and have been propagated in vitro in
a variety of culture systems. Using a serum-free unsupplemented media condition, NSCs spontaneously differentiated
into bIII-tubulin-, glial fibrillary acidic protein (GFAP)-, and
04-immunopositive cells, markers for neurons, astrocytes,
and oligodendrocytes, respectively. As described in the
Examples below, NSCs treated according to methods of the
invention migrate and differentiate into neurons and glia after
transplantation into the brains of 24-month-old rats and significantly improved the cognitive functions of these animals.
This result suggested that more developmentally potent cells
produced according to the invention could provide transplantable material to produce a retinal stem cell alternative.
There is a variety of factors involved in the development of
retinal tissue that regulate the proliferation and differentiation
ofretinal cells. Transforming growth factor beta-3 (TGF-b3)
is thought to regulate cell proliferation during development
and also influence the commitment or the differentiation, or
both, of neural progenitor cells to retinal fates. Treatment of
embryonic day-18 rat retinal cultures with TGF beta-like
protein, activinA, causes the progenitor cells in these cultures
to exit the cell cycle and differentiate into rod photoreceptors,
indicating that the TGF-family is an important regulator of
photoreceptor differentiation in the developing retina. Treatment of the more developmentally potent cells prepared
according to the invention with an effective amount of growth
factor selected from the group consisting ofTGF-b3, IGF-1
and CNTF, for an effective period, can induce their adoption
of a retinal differentiation path. That is, more developmentally potent cells of the invention, regardless their origin, can
be made to adopt a retinal differentiation path. Cells not
treated according to the methods of the invention do not so
differentiate with simple exposure to these growth factors.
Using the methods of the invention, less developmentally
potent cells can be transformed into more developmentally
potent cells and subsequently used as alternatives to retinal
stem cells to repair ocular tissue damage or promote tissue
regeneration.
As described above, "retinal differentiation," as used
herein, refers to the various cell types found in eye tissue, inter
alia, chorid, Buchs and retinal pigment epithelium cells, rod
and cone photoreceptor cells, horizontal cells, bipolar neurons, amacrine, ganglion and optic nerve cells. These nonlimiting, exemplary cell types found in eye tissue are collectively referred to as retinal cells.
The inventive methods use substituted deoxynucleotide or
deoxynucleoside compounds to change the cell fate decisions
ofless developmentally potent cells to more developmentally
potent cells. In the case of retinal transplants, these more
developmentally potent cells are treated with an effective
amount of growth factor selected from the group consisting of
TGF-b3, IGF-1 and CNTF, for an effective period to encourage their commitment change to the retinal cell lineage.
There are a variety of neurological and corporal deficits
that can be addressed using the more developmentally potent
cells of the invention.

Retinal Related
Retinal degenerative diseases, including macular degeneration, are major causes of blindness. Despite investigations
into gene therapy, growth/survival factor injections and vitamin treatments, no effective vision-restoring treatments are
currently available. Visual impairment caused by the degeneration of photoreceptors or neural cells has been considered
incurable because of a long-held "truism" that neurons do not
regenerate during adulthood. However, this statement has
been challenged and there is new evidence that these cells do
indeed have the potential to be renewed after maturation, thus
opening a door for the development of novel therapies to treat
visual impairment by retinal regeneration using stem cell
transplantation.
The capacity for retinal regeneration in cold-blooded vertebrates has long been recognized. Fish and amphibians continue to make new retinal neurons through a population of
retinal stem cells residing at the peripheral margin of the
retina, the so-called "ciliary marginal zone." Recent studies
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"Neurological Deficits" Amenable to Treatment
Because the invention relates in part to the discovery that
multipotent precursor cells can be stimulated to divide and
migrate through the brain, such MSCs can be used to treat
neurological deficits caused by a wide variety of diseases,
disorders, and injuries. These insults include, but are not
limited to, the following.

(wet or dry), post-surgical healing, tumor, heritable retinal
dystrophies, optic nerve atrophy, and other retinal degenerative diseases. Cells targeted for repair utilizing cells and
methods of the invention include, for example, choroids,
Buchs, retinal pigment epithelial (RPE), rods, cones, horizontal cells, bipolar neurons, amacrine, ganglion, and optic
nerve.

Degenerative Diseases
Degenerative diseases that can be treated according to the
methods of the invention include Alzheimer's disease (AD),
Parkinson's disease (PD), Huntington's disease (HD), Pick's
disease, progressive supranuclear palsy (PSP), striatonigral
degeneration, cortico-basal degeneration, childhood disintegrative disorder, olivopontocerebellar atrophy (OPCA;
including a heritable form), Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as
Krabbe's disease, Pelizaeus-Merzbacher disease, and the
like), amaurotic (familial) idiocy, Kuf's disease, SpielmayerVogt disease, Tay Sachs disease, Batten disease, JanskyBielschowsky disease, Reye's disease, cerebral ataxia,
chronic alcoholism, beriberi, Hallervorden-Spatz syndrome,
and cerebellar degeneration.
Traumatic and Neurotoxic Injuries to the Central Nervous
System
Traumatic and neurotoxic injuries that can be treated
according to the methods of the invention include gunshot
wounds, injuries caused by blunt force, injuries caused by
penetration injuries (e.g., stab wounds), injuries caused in the
course of a surgical procedure (e.g., to remove a tumor or
abscess from the CNS or to treat epilepsy), poisoning (e.g.,
with MPTP or carbon monoxide), shaken-baby syndrome,
adverse reactions to medication (including idiosyncratic
reactions), drug overdose (e.g., from amphetamines), and
post-traumatic encephalopathy.
Ischemia
Any disruption of blood flow or oxygen delivery to the
nervous system can injure or kill cells, including neurons and
glial cells, therein. These injuries can be treated according to
the methods of the present invention and include injuries
caused by a stroke (including a global stroke (as may result
from cardiac arrest, arrhythmia, or myocardial infarction) or
a focal stroke (as may result from a thrombus, embolus,
hemorrhage, or other arterial blockage)), anoxia, hypoxia,
partial drowning, myoclonus, severe smoke inhalation, dystonias (including heritable dystonias ), and acquired hydrocephalus.
Developmental Disorders
Developmental disorders that can be treated according to
the methods of the invention include schizophrenia, certain
forms of severe mental retardation, cerebral palsy (whether
caused by infection, anoxia, premature birth, blood type
incompatibility: etc. and whether manifest as blindness, deafness, retardation, motor skill deficit, etc.), congenital hydrocephalus, metabolic disorders affecting the CNS, severe
autism, Down Syndrome, LHRH/hypothalamic disorder, and
spina bifida.
Disorders Affecting Vision
Disorders affecting vision, particularly those caused by the
loss or failure of retinal cells, can be treated according to the
methods and cells of the invention. These disorders include,
for example, diabetic retinopathy, serious retinal detachment,
retinal damage associated with glaucoma, traumatic injury to
the retina, retinal vascular occlusion, macular degeneration
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Injuries and Diseases of the Spinal Cord
Injuries to or diseases affecting the spinal cord can also be
treated according to the methods of the invention. Such injuries or diseases include post-polio syndrome, amyotrophic
lateral sclerosis, nonspecified spinal degeneration, traumatic
injury (such as those caused by automobile or sporting accidents), including any injury that crushes, partially severs,
completely severs, or otherwise adversely affects the function
of cells in the spinal cord), injuries caused by surgery to the
spinal cord (e.g., to remove a tumor), anterior horn cell disease, and paralytic diseases.
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Demyelinating or Autoimmune Disorders
Neurological deficits caused by demyelination or an
autoimmune response can be treated according to the methods of the invention. Such deficits can be caused by multiple
sclerosis, or lupus.
Infectious or Inflammatory Diseases
Neurological deficits caused by an infection or inflammatory disease can be treated according to the methods of the
invention. Infections or inflammatory diseases that can cause
treatable deficits include Creutzfeldt-Jacob disease and other
slow virus infectious diseases, AIDS encephalopathy, postencephalitic Parkinsonism, viral encephalitis, bacterial meningitis and meningitis caused by other organisms, phlebitis
and thrombophlebitis of intracranial venious sinuses, syphilitic Parkinsonism, and tuberculosis of the CNS.
In addition to the deficits, diseases and disorders set forth
explicitly above, those of ordinary skill in the art are well able
to recognize neurological deficits, regardless of their cause,
and to apply the methods of the present invention to treat
patients who have such deficits. In addition to the conditions
listed above, that are amenable to treatment with the methods
described herein, neurological deficits can be caused by
Lesch-Nyhan syndrome, myasthenia gravis, various dementias, numerous parasitic diseases, and epilepsy. Further, alleviation of age-related memory loss is an object of the invention. The methods of the invention can be readily applied to
alleviate neurological deficits caused by these and other diseases, disorders, or injuries.
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"Corporal Deficits" Amenable to Treatment
The invention also relates to the amelioration of corporal
deficits utilizing multipotent precursor cells stimulated to
divide, migrate through damaged tissue and differentiate in a
tissue-specific manner. Cells according to the invention can
be used to treat corporal deficits caused by a wide variety of
diseases, disorders, and injuries, the result of which is trauma,
malfunction, degeneration or loss of muscle such as, for
example, cardiac muscle due to myocardial infarction. Other
examples include malfunction, degeneration or loss of other
cells and tissues apart from those discussed in the neurological deficit section above such as, for example, internal organs.
For example, liver function can be adversely affected by,
among other things, disease (e.g., cirrhosis or hepatitis),
trauma or age. Other exemplary internal organs amenable to
treatment utilizing the embodiments of the invention include
heart, pancreas, kidney, stomach, and lung. Corporal deficits
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also comprise malfunction, degeneration or loss of skeletal
assets such as, for example, vertebrae.

now know that reelin is expressed in several neuronal populations in the adult brain (Pesold et al., 1998, Proc. Natl. A cad.
Sci. USA 95: 3221-6; Pesold et al., 1999, Proc. Natl. Acad.
Sci. USA 96: 3217-22). This protein is thought to be operative
in other important functions, for example, the reelin haploinsufficient heterozygous reeler mouse exhibits decreased dendritic spine expression density in pyramidal neurons of the
cortex and hippocampus and reelin and alpha-3-integrin (a3integrin) receptor subunit immunoreactivities colocalize to
dendritic spine postsynaptic densitie, which supports a role
for reelin in adult brain neuroplasticity (spine formation and
synaptogenesis) that requires protein synthesis. Such studies
draw a reasonable connection to the observation that
depressed reelin levels have been observed in victims of
schizophrenia and autism. Deficiencies in neuroplasticity and
stem cell migration could be seen to reduce or prevent the
endogenous stem cell population or exogenous, more developmentally potent cells of the invention from migrating to the
regions of need in the brain.
Our studies indicate that reelin plays an important role in
regulation ofNSC biology. The addition of recombinant reelin to NSCs in culture increased mobility of cells in the cluster
of cells that typified their growth. When NSCs were transplanted in the brain of reeler homozygous mice, mice that do
not express reelin, migration was nearly halted; in contrast,
NSCs migrated and displayed a beautifully symmetrical distribution in wild-type mice brain after transplantation. We
found that only cells expressing reelin migrated into the cortex of reeler homozygous mice. These results suggest that
reelin is an indispensable factor for the migration ofNSCs or
more developmentally potent cells of the invention, and the
epigenetically downregulated reelin expression in schizophrenia and autism patients causes a deficit in migration and
neuroplasticity potentially associated with those phenotypes.
Reelin is preferentially expressed in GABAergic neurons in
the adult cortex, so some of the loss ofGABAergic interneurons in the neocortex of schizophrenia may be explained by
this mechanism as well.
Mammals with suppressed reelin expression may not experience proper migration of endogenous or exogenous multipotent cells in the brain. Thus, reelin levels could be raised
through genetic engineering approaches, i.e., the introduction
of cells expressing reelin or appropriate vectors for endogenous cells transfection, to stimulate migration at the possible
expense of some additional glial differentiation. The reelin
protein can be administered to a mammal in need. For
example, reelin can be introduced at the site of a stroke to
encourage the migration of multipotent cells into the area of
damage to start repair. Drugs that increase reelin expression
or reelin levels in general may also be administered in an
amount sufficient to raise reelin levels enough to enable
proper migration. Similarly, the biological activity of the
reelin present in an animal depends also on reelin receptor.
Altering reelin receptor abundance or affinity for reelin can
enhance the activity or suppress the activity of any reelin
preset in the animal. The present invention contemplates the
use genetic techniques to supplement or alter the natural
supply of reelin receptors through genetic techniques well
known in the art to influence cell migration. Similarly, the
invention provides a method of altering the differentiation of
endogenous or exogenous multipotent stem cells in a mammal by altering the amount or binding affinity ofAPP receptor
in the mammal. Such methods may help those afflicted with
schizophrenia and autism.

Reelin andAmyloid Precursor Protein (APP)
Reelin
Neurogenesis in animals lacking the more developmentally potent cells of the present invention is dependent on
endogenous NSCs. Islands of NSCs have been detected in
embryonic and adult mammalian brains, and due to their
pluripotent differentiation potential, they can differentiate
into astrocytes, neurons, or oligodendrocytes. Recent studies
have observed NSCs in the anterior subventricular zone
(SVZ) and dentate gyrus of the adult brain, indicating that
neurogenesis may occur throughout life. Although pluripotency of endogenous, adult NSCs is regionally and temporally restricted, these cells retain their ability to migrate and
differentiate in response to environmental cues. As described
in Example 1 below, human NSCs that were injected into the
lateral ventricle of 24-month-old rats showed a symmetrical
migration in the host brain followed by differentiation into
neurons and glial cells. This result indicates that the aged
brain maintains regulatory mechanisms to guide the migration of NSCs, and exogenous more developmentally potent
cells of the invention, that may be indispensable for proper
adult brain neuroplasticity.
Recent studies (Corbin et al., 2001, Nat Neurosci 4 Supp. 1:
1177-827; Marin et al., 2001, Nat Rev Neurosci 2: 780-901)
have revealed two distinct neuronal migration patterns: radial
and tangential. Each pattern consists of two different neuronal populations that participate in corticogenesis. One neuronal population proliferates from the embryonic SVZ and
migrates along the radial glia to reach the subcortical plate,
detaches from radial glia scaffolding, and then penetrates the
subcortical plate guided by reelin gradient secreted by
gamma amino butyric acid (GABA)-ergic Cajal-Retzius cells
(D'Arcangelo et al., 1995, Nature 374: 719-23). A second
neuronal population consists of tangentially migrating neuroblasts that proliferate in the SVZ in the mantle of ganglionic
telencephalic eminences and give rise to GABA-producing
inter-neurons (Anderson et al., 2001, Development 128: 35363). In the adult brain, host glial cells respond to the transplantation of NSCs (Leavitt et al., 1999, Exp. Neural 157:
43-57) and lesions (Yang et al., 1997, Exp Neurol 146: 199205) by becoming transient radial gliatype cells, which may
serve to guide migration in adult neurogenesis. In contrast,
subsets of cells expressed in the ventral piriform cortex and
olfactory bulb migrate long distances without a radial glia
connection (Durbec et al., 2001, Mal Cell Neurosci 17: 56176), suggesting that specific regulatory mechanisms guide
NSC migration in the adult brain and that some of these
mechanisms are very likely analogous to those operative during development.
Reelin is a large extracellular matrix (ECM) protein of
approximately 400 kDa, which binds to the a3 subunit of
integrin receptors expressed on neuronal cell surfaces, very
low density lipoprotein receptor (VLDLR) and Apolipoprotein E receptor 2 (ApoER2 ), triggering the adaptor function of
the disabled-I (Dab-1) cytosolic protein. The clustering of
integrin receptor subunits following reelin binding activates a
tyrosine kinase (focal adhesion kinase) to phosphorylate
Dab-1. This phosphorylated Dab-1 binds and transports
soluble tyrosine kinases and transcription factors to functional cellular compartments. In the null reeler mouse,
migrating neurons fail to penetrate the subcortical plate,
likely due to a deficiency of serine protease activity associated with reelin. While much attention has been focused on
role of reelin in neuronal migration during corticogenesis, we
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Thus the alteration of reelin levels may be used to influence
the migration of endogenous NSCs as well as exogenous
multipotent cells such as the more developmentally potent
cells of the invention.

N-terminal of APP prevents the differentiation of NSCs.
These findings indicate that APP signaling is one of the regulatory systems involved in the differentiation of NSCs. We
also found that NSCs transplanted into the APP knockout
mouse brain could not migrate properly and failed to repair
brain lesions, whereas NSCs transplanted into wild-type
mouse successfully migrated into the proper position and
differentiated in a tissue-appropriate manner. This result is
not only the first finding of a phenotypical change in APPknockout mice, but also indicates a physiological role for
APP in the regeneration of adult brain cells. Furthermore, we
found that the addition of a higher concentration of sAPP or
the over-expression of APP by transgenes to NSC cultures
caused glial rather than neural differentiation of these cells.
These findings indicate that the pathological alteration of
APP metabolism inAD induces glial differentiation of neural
stem cells and could leads to the exhaustion of the stem cell
population, which may be important for ongoing neurogenesis in the adult brain.
To prevent or remedy any exhaustion of endogenous stem
cell populations in the brain, more developmentally potent
cells of the invention can be administered according to the
methods of the invention to the mammal with increased APP
production. Such action may act to overwhelm the excess
APP such that increased glial differentiation of the multipotent cells is nevertheless accompanies with significant proper
migration and differentiation to replace degenerating neurons. Alternatively, anti-APP antibody can be used to lower
excessive APP levels. Anti-APP antibody can be administered to the mammal with overabundant APP such that the
APP levels are reduced in an amount sufficient to prevent glial
differentiation of the endogenous or exogenous multi potent
stem cell population. Genetic engineering methods can be
used to introduce a vector that expresses anti-APP antibody in
the mannnal with elevated APP levels. Such a method prevents the need for repeated administration of the antibody
protein itself. Furthermore, drugs that lower APP expression
or APP levels in general can be administered.
Mannnals with suppressed APP expression may not experience proper migration of endogenous or exogenous multipotent cells in the brain. Thus, APP levels could be raised
through genetic engineering approaches, the introduction of
cells expressing APP or appropriate vectors for endogenous
cells transfection, in some instances expressing at relatively
low levels, to stimulate migration at the possible expense of
some additional glial differentiation. The APP protein can be
administered to a mannnal in need. For example, APP can be
introduced at the site of a stroke to encourage the migration of
multipotent cells into the area of damage to start repair. Glial
differentiation is an important part of the healing process in
the brain. Drugs that increase APP expression or APP levels in
general may also be administered in an amount sufficient to
raise APP levels enough to enable proper migration.
As with reelin, the biological activity of the APP present in
an animal depends also on APP receptor. Altering APP receptor abundance or affinity for APP can enhance the activity or
suppress the activity of any APP preset in the animal. The
present invention contemplates the use genetic techniques to
supplement or alter the natural supply of APP receptors
through genetic techniques well known in the art to influence
cell migration and/or proliferation.
Thus the alteration of APP levels may be used to influence
the migration and differentiation of endogenous NSCs as well
as exogenous multipotent cells such as the more developmentally potent cells of the invention.
An advantage of the cells of the invention is that they can be
genetically engineered according to routine procedures

APP
While many factors are released following apoptotic cell
death, several studies point to an important correlation
between apoptosis and the amyloid precursor protein (APP).
Damaged neurons and neurons committed to apoptosis demonstrate signals strongly immunopositive for APP. Moreover,
amyloidgenic fragments produced from APP are released into
the extracellular space from neuronal cells under serum-deprived conditions. The expression of APP is also reported to
increase during retinoic acid-induced neuronal differentiation. The mRNA expression of beta-amyloid (b-amyloid)
precursor-like proteins (APLP-1 and APLP-2) is also upregulated during retinoic acid induced differentiation of
human SH-SY5Y neuroblastoma cells. The increase in APP
expression levels during neuronal differentiation in various
cell culture systems suggests an important cellular function
for APP during the differentiation process. From these observations, it appears that under serum-free differentiation conditions, APP fragments released from apoptotic cells serve as
regulation and differentiation factors for neighboring stem
cells.
APP is also known to be up-regulated during development
and after brain damage, both of which are events that involve
migration and differentiation ofNSCs. Secreted APP (sAPP)
has also been reported to produce protein kinase C and synaptogenesis in cultured neurons, in addition to significantly
enhancing proliferation and growth of neural stem cells.
Moreover, it has been shown that sAPP is able to activate
MAPK (ERK) in PC12 cells via the Ras pathway. Since
MAPK activation can induce proliferation or differentiation,
sAPP may activate this pathway in proximal stem cells and
induce cell differentiation. These facts, together with several
of the examples below, indicate that one ofAPP's physiological functions may be the regulation of stem cell biology in the
brain to allow forthe successful formation and replacement of
proper structures and neuronal circuits. sAPP released from
damaged or dying cells may preferentially induce glial differentiation of a population of NSCs and this may act to
reconstruct neuronal circuits by the guidance of NSCs to
areas of damage. The stem cell-derived glial cells can then
produce factors that can support surrounding damaged cells
and promote neuronal migration and differentiation of other
NSCs in this area. Our in vitro observations that the initial
apoptotic cell death-induced glial differentiation was followed by neuronal differentiation (Brannen et al., 2000, Neuroreport 11: 1123-8) supports this view. Thus, under normal
physiologic conditions, APP can be necessary to recover from
brain damage. In the case of familial AD, the increased levels
ofAPP fragments produced in the brains of these patients may
modify the biological equilibrium ofNSCs in such a way that
a pathological shift towards premature differentiation of
NSCs will occur, thereby depleting or exhausting the NSC
population. Since the effective natural replacement of degenerating neurons in the adult brain during aging or disease
process may be important in maintaining normal brain function, the NSC population exhaustion would hinder such
replacement.
In preliminary studies, we found evidence that APP fragments are secreted from apoptotic HNSCs and induce differentiation of other NSCs in vitro. We also observed that exogenously added secreted-type APP (sAPP) induces the
differentiation of NSCs, while antibody-recognizing the
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known in the art (See, e.g., SAMBROOK, ET AL.,
MOLECULAR CLONING: A LABORATORY MANUAL.
3Rn EDITION, COLD SPRING HARBOR LABORATORY,
2001 ). As mentioned above, in preferred embodiments, constructs encoding reelin can be provided to the cells. In other
preferred embodiments, constructs that inhibit expression of
APP (such as ribozymes, antisense molecules, or other means
of inhibiting APP expression) can be provided. In further
embodiments, drug resistance genes and markers, or detectable markers such as GFP can be provided. Preferably, the
marker and other genes are operably and genetically linked to
gene expression regulatory elements (including but not limited to promoters and enhancers) that are operable in the
terminally differentiated cell derived from MSCs of the
invention or in the undifferentiated MSCs of the invention or
both.
The following examples are presented in order to more
fully illustrate the preferred embodiments of the invention.
They should in no way be construed, however, as limiting the
scope of the invention, as defined by the appended claims.

These behavioral results indicate the beneficial effects of
the transplantation ofBrdU-treated human NSCs into the host
brain. After the second water maze task, postmortem brains
were further analyzed by immunohistochemistry for human
bIII-tubulin and human GFAP, markers for neurons and astrocytes respectively. There was no sign of ventricular distortion,
no evidence of tumor formation, and no strong host anti-graft
immunoreactivity was observed as revealed by weak host
astrocyte staining. Intensely and extensively stained with
bIII-tubulin, neurons with BrdU-positive nuclei were found
in bilateral singular and parietal cortexes (FIGS. 4a-c) and
hippocampus (FIGS. 4d,e). The bIII-tubulin-positive neurons
found in the cerebral cortex were typified by a dendrite pointing to the edge of the cortex. In the hippocampus, donorderived neurons exhibited multiple morphologies, varying in
cellular size and shape, and one or more processes and
branching.
Generally, GFAP-positive astrocytes were localized near
the area where neuronal cells were found. On further analysis
(overlapping images of their distributions), donor-derived
astrocytes were found to co-localize with neuronal fibers in
the cortex (FIG. 4/). These astrocytes were larger than the host
glia, with cell bodies 8-10 microns in diameter and thick
processes. Some of these astrocytes had a unilateral morphology (asymmetric), and the immunostaining formed a thin ring
around the nucleus, while the majority of the processes were
formed on the other side. Most cells appeared a symmetrical
with processes forming from all sides. The absence of this
type of cell in normal animal without the transplantation of
treated human NSCs was confirmed using immunohistochemistry for rat astrocytes. host astrocytes had small cell
bodies with multiple delicate processes, and were distributed
throughout the brain mainly in white matter and around the
edges of the brain.
These results demonstrated that transplanted cells of the
invention migrated in rat brain and differentiated into appropriate cell types. The concomitant improvement in cognitive
function indicated that transplanted more developmentally
potent cells of the invention were functionally integrated into
the recipient brains.
The following methods were used in this and several of the
following examples:
The Morris Water Maze: The Morris water maze consists
of a large circular tank (diameter, 183 cm; wall height, 58 cm),
filled with water (27° C.) and opacified by the addition of
powdered milk (0.9 kg). Beneath the water surface (1 cm)
near the center of one of the four quadrants of the maze a clear
escape platform (height, 34.5 cm) is positioned. The rats
receive three training trials per day for seven consecutive
days, using a 60 sec inter-trial interval. A training trial consists of placing the animal in the water for 90 seconds or until
the swimming rat successfully locates the platform. If the rat
fails to find the platform within the 90 seconds, the animal is
gently guided to the platform. For spatial learning assessment, the platform's location remains constant in one quadrant of the maze, but the starting position for each trial is
varied. Every sixth trial is a probe trial, during which the
platform is retracted to the bottom of the pool for 30 sec and
then raised and made available for escape. The training trials
assess the acquisition and day-to-day retention of the spatial
task while the probe tests are used to assess search strategy. At
the completion of a spatial learning assessment, one session
with six trials of cue training is performed Rats are trained to
escape to a visible black platform that is raised 2 cm above the
surface of the water. The location of the platform is varied
from trial to trial to assess sensorimotor and motivational
functioning independent of spatial learning ability. Each rat is
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Improvement of Cognitive Function in Aged Rat by the
Transplantation ofNSCs of the Invention
Human NSCs do not require any exogenous factors for
differentiation and survived more than three weeks in basal
media without the addition of any factor to support their
survival (Qu et al., 2001, Neuroreport 12: 1127-32). Thus, it
appears that human NSCs produce factors to differentiate and
support themselves, which suggested that these cells could be
transplanted into aged animals after treatment according to
the methods of the invention.
Human NSCs, expanded without differentiation under the
influence of mitogenic factors in supplemented serum-free
media and pre-treated by the incorporation of bromodeoxyuridine (BrdU) into the nuclear DNA, were injected into the
lateral ventricle of mature (6-month-old) and aged (24month-old) rats. Human NSCs prepared according to the
methods of the invention survived 30 days after xenotransplantation into aged rat brain, while retaining both multipotency and migratory capacity, and also improved cognitive
function in 24-month-old rats. Cognitive function of the animals was assessed by the Morris water maze both before and
four weeks after the transplantation of human NSCs of the
invention. Before human NSC transplantation, some aged
animals (aged memory unimpaired animals) cognitively
functioned in the range of mature animals, while others (aged
memory impaired animals) functioned entirely out of the
cognitive range of the mature animals. After transplantation
of the BrdU-treated human NSCs, most aged animals had
cognitive function in the range of the mature animals. Strikingly, one of the aged memory-impaired animals showed
dramatic improvement in its behavior, functioning even better
than the mature animals (FIG. 2a ). Statistical analysis showed
that cognitive function was significantly improved in both
mature and aged memory-impaired animals but not in aged
memory-unimpaired animals after BrdU-treated human NSC
transplantation (FIG. 2b ), which may be due to the physical
limitations of the aged animals. The performance of three of
the aged animals deteriorated in the water maze after transplantation of treated human NSCs. It is possible that the
physical strength of these animals deteriorated during the
experimental period.
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given 30 seconds to reach the platform and is allowed to
remain there briefly before the 30 second inter-trial interval.
Accuracy of performance is assessed using a learning index
score computed from the probe trials. The learning index is a
derived measure from average proximity (cumulative search
error divided by the length of the probe trial) on the second,
third, and fourth interpolated probe trials. Scores from these
trials are weighted and summed to provide an overall measure
of spatial learning ability. Lower scores on the index indicate
a more accurate search near the target location; higher scores
indicate a more random search and poor learning.
Cell migration and differentiation: In order to investigate
differentiation and/ or migration of cells of the invention in the
brain, more developmentally potent cells were transplanted
into rodent brain. The animals were anesthetized with 50
mg/kg pentobarbital (i.p.) and mounted in a stereotaxic apparatus (David Kopi). Approximately lxl04 to lxl05 cells in 5
µl phosphate-buffered saline were injected into the ventricle
using a microsyringe attached to the stereotaxic apparatus.
After removing the hair from the surgical site using electric
razor, an iodine swab was be applied to the area and a 0.5 cm
surgical incision was made caudal to rostral in the skin at the
surface of the cranium. The ventricle was stereotaxically
localized using the following exemplary coordinates: AP=0.58 mm from bregma, ML=+ 1 mm, and 2.4 mm below dura
(for mouse): AP=-1.4 mm from bregma, ML=+3.3 mm, and
4.5 mm below dura (for rat). A 0.4-mm hole was made in the
cranium by careful drilling. The cells of the invention were
injected into the ventricle using a microsyringe. The injection
was delivered over a period of five minutes and the needle was
left in place for an additional two minutes following the
injection. After the injection, the surgically incised skin was
closed by Michel suture clip (2.5xl .75 mm). Ten days postsurgery, proper healing of the incision site was observed, and
the Michel sutures were removed.
Cell migration and differentiation: In order to investigate
differentiation and/ or migration of cells of the invention in the
brain, more developmentally potent cells were transplanted
into rodent brain. The animals were anesthetized with 50
mg/kg pentobarbital (i.p.) and mounted in a stereotaxic apparatus (David Kopf). Approximately lxl04 to lxl0 5 cells in 5
µl phosphate-buffered saline were injected into the ventricle
using a microsyringe attached to the stereotaxic apparatus.
After removing the hair from the surgical site using electric
razor, an iodine swab was be applied to the area and a 0.5 cm
surgical incision was made caudal to rostral in the skin at the
surface of the cranium. The ventricle was stereotaxically
localized using the following exemplary coordinates: AP=0.58 mm from bregma, ML=+ 1 mm, and 2.4 mm below dura
(for mouse): AP=-1.4 mm from bregma, ML=+3.3 mm, and
4.5 mm below dura (for rat). A 0.4-mm hole was made in the
cranium by careful drilling. The cells of the invention were
injected into the ventricle using a microsyringe. The injection
was delivered over a period of five minutes and the needle was
left in place for an additional two minutes following the
injection. After the injection, the surgically incised skin was
closed by Michel suture clip (2.5xl .75 mm). Ten days postsurgery, proper healing of the incision site was observed, and
the Michel sutures were removed.
The existence and location of the cells of the invention after
administration in rat brain was analyzed as follows. At 30
days post-transplantation, the rats were sacrificed by an overdose of sodium pentobarbital (70 mg/kg, i.p.) and perfused
with phosphate buffered saline (PBS) followed by 4%
parafonnaldehyde. Brains were removed and incubated overnight in 4% paraformaldehyde fixative containing 20%
sucrose. The brains were sliced into 20 micron coronal sec-

tions using a cryomicrotome. The sections were washed
briefly in PBS and pretreated with IM HCl for 30 minutes at
room temperature and neutralized with sodium borate (0.1 M,
pH 8.0) for 30 minutes in order to increase the accessibility of
an anti-BrdU antibody to BrdU incorporated :in the cell
nuclei. After rinsing with PBS, sections were transferred to a
solution containing 0.25% Triton X-100 in PBS (PBST) for
30 minutes. The sections were then blocked by incubation in
PBST containing 3% donkey normal serum for 1 hour, followed by incubating the sections overnight at 48° C. with
sheep anti-BrdU (1: 1000; Jackson IR Laboratories, Inc. West
Grove, Pa.) or mouse anti-BrdU (1:200; DSHB, Iowa City,
Iowa) diluted in PBST. After rinsing the sections in PBS,
donkey anti-mouse or donkey anti-sheep conjugated to
rhodamine IgG (Jackson IR Laboratories, Inc.) was added at
a 1:200 dilution in PBST and the sections further incubated
for 2 hours at room temperature in the dark.
The transplanted cells of the invention, with BrdU immunopositive nuclei, were stained for human bIII-tubulin and
human glial filament protein (GFAP). The sections were then
washed with PBS and incubated with mouse IgG2b monoclonal anti-human bIII-tubulin, clone SDL3D10 (1:500,
Sigma), goat antihuman GFAP, N-terminal human affinity
purified (1:200, Research Diagnostics Inc., Flander, N.J.) or
mouse IgGl monoclonal anti-GFAP, clone G-A-5 (1:500,
Sigma), respectively, overnight at 48° C. in the dark. After
brief washing with PBS to remove excess primary antibody,
the location of primary antibody binding was then determined
using FITC-conjugated (Jackson IR Laboratories, Inc.) secondary antibody (donkey anti-mouse (1:200) or donkey antigoat IgG (H+L; 1:200), respectively) by incubating the sections for 2 hours at room temperature in the dark.
The sections were then washed with PBS thoroughly
before mounting to glass slides. The mounted sections were
covered with Vectashield using 4',6-diamidine-2-phenylindole. 2HC1 (DAPI, Vector Laboratories, Inc., Burlingame,
Calif.) for fluorescent microscopic observation. Microscopic
images were taken by using an Axiocam digital camera
mounted on the Axioscope 2 with Axiovision software
(Zeiss).
The transplanted MNSCs, with BrdU immunopositive
nuclei, were stained for human bIII-tubulin and human GFAP.
Double immunolabeling with bIII-tubulin and BrdU in three
different planes from the same microscopic view clearly
showed the co-localization of these two signals in the same
cells (FIG. 5). According to the manufacturer's description,
the anti-bIII-tubulin antibody may also recognize the host
(rat) bIII-tubulin. Despite this, the specific co-localization of
the bIII-tubulin and BrdU at different planes indicate that the
majority of bIII-tubulin immunopositive cells were indeed
transplanted cells of the invention. This may be because bIIItubulin is mainly expressed in immature neurons, the majority of which are transplanted cells as disclosed herein. The
presence of these cell specific antigens indicates that the
transplanted cells of the invention successfully differentiated
into neurons and astrocytes, respectively.
NSC culture: NSCs were purchased (Bio Whittaker, Walkersville, Md.), and alternatively isolated from human tissue,
and cultured in a nonsupplemented, serum-free basal medium
comprising HAMS-F12 (Gibco, BRL, Burlington, ON); antibiotic-antimycotic mixture (1:100, Gibco ); B27 (1:50,
Gibco ); human recombinant FGF-2 and EGF (20 ng/ml each,
Rand D Systems, Minneapolis, Minn.) and heparin ( 5 ug/ml,
Sigma, St. Louis, Mo.). The cells were incubated at about 37°
C. in a 5% C0 2 humidified incubation chamber (Fisher, Pittsburgh, Pa.). To facilitate optimal growth conditions, clusters
of one or more NSCs were sectioned into quarters every 2
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weeks and fed by replacing 50% of the medium every 4-5
days. To inhibit differentiation, the cells can be propagated on
uncoated flask or a flask that has been treated to repel the cells.
To induce differentiation, these cells can be replated in the
culture dishes (about lxl0 5 per dish) in the serum-free basal
medium Eagle (BME), which comprises Earle's salt and
L-glutamine, and cultured for about 5 days in the absence of
FGF-2 and EGF and without the addition of other extrinsic
differentiation factors. NSCs cultured in this serum-free
medium can spontaneously undergo differentiation into neuronal cell types.

cell populations, including neural precursors that formed a
cluster of two or more cells in the middle, and coronary
migrating immature and/or mature neurons and astrocytes
(FIG. 7). MeSCs treated with BrdU were then transferred
onto a tissue culture 0.4 µm membrane insert (Falcon) and
placed on top of the differentiated NSCs in basal media conditions.
Immunocytochemical examination seven days post-coculture revealed that BrdU-treated MeSCs differentiated into
bIII-tubulin immunopositive small bipolar and unipolar cells
(approximately 40% of total cells), and GFAP-immunopositive large flattened multipolar cells (approximately 60% of
total cells) (FIG. 8). Although the process of bIII-tubulin
immunopositive cells derived from MeSCs was shorter than
those found in differentiated NSCs, the general morphology
of the cells in both NSCs and MeSCs-differentiated cultures
were similar (FIG. 8). This result indicated that BrdU pretreated MeSCs are capable of becoming neurons and astrocytes when co-cultured with differentiated NSCs. On the
other hand, MeSCs without BrdU treatment did not express
either bIII-tubulin or GFAP immunoreactivity and remained
in a fibroblast-like morphological state even after co-culture,
demonstrating clear evidence that substituted deoxynucleotide or deoxynucleoside treatment is necessary to initiate
neural lineage change in MeSCs.
Since no exogenous differentiation factors such as, for
example, retinoic acid and BDNF (brain derived neurotrophic
factor) were added to cultures, and no cell-to-cell contact
existed in this co-culture system, it appears that membrane
permeable endogenous factor( s) were released from differentiating NSCs and altered the cell fate decisions of BrdUtreated MeSCs in a manner not possible with non-treated
MeSCs. That is, BrdU-treated MeSCs acted as more developmentally potent cells, in this case like NSCs, which are
capable of responding to neural environmental cues.
MeSCs culture: Though they can be isolated utilizing
numerous methods well known in the are, for the present
examples, human MeSCs were purchased (Bio Whittaker,
Walkersville, Md.) and selected by negative selection for
CD 11 b, CD33, CD34, and CD 133 antigens. The MeSCs were
cultured in, for example, 20 ml of serum-supplemented
growth medium consisting of Dulbecco's Modified Eagle
Medium (Gibco, BRL, Burlington, ON); antibiotic-antimycotic mixture (Gibco); and FBS MesenCult Medium (Stem
Cell Technologies, Vancouver, BC). The cells were incubated
at 3 7° C. in a 5% C0 2 humidified incubation chamber (Fisher,
Pittsburgh, Pa.). The cells were fed by replacing half the
culture media twice per week. After 60 passages, the cells
were still negative for the above-listed antigens. Before in
vitro and in vivo differentiation, human MeSCs were treated
with different doses (10 nM-100 µM) of 5-bromo-2-deoxyuridine (BrdU, Sigma) for various durations (24-240 hr). To
investigate whether DNA methylation is involved in the BrdU
effect, cells were treated with BrdU in the presence of 5-azacytidine (0.3-1 mM). The preceding growth conditions are
applicable to cell types other than MeSCs, such as, for
example, NSCs and other stem cells.
Co-cultures of human MeSCs and NSCs: Human NSCs
(about lxl04 to lxl05 ) were differentiated in serum-free
basal medium Eagle (BME, Gibco), which contains Earle's
salt and L-glutamine for five days in a 12-well culture plate
before co-culture in the absence of FGF-2 and EGF and
without the addition of other extrinsic differentiation factors.
Under these condition, NSCs spontaneously differentiated
into neurons and glia. For the co-culture experiments, BrdUtreated human MeSCs (about lxl04 to lxl05 ) were transferred into cell culture inserts with a pore size of 0.4 µm
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Example 2
Neural Differentiation ofMeSCs In Vitro
Neural stem cells have been isolated from embryonic and
adult mammalian and human (Doetsch et al., 1999, Cell 97:
703-16; Johansson et al., 1999, Cell 96: 25-34) central nervous system (CNS) and propagated in vitro in a variety of
culture systems (Svendsen et al., 1999, Brain Pathol. 9: 499513). The inability to grow neural progenitors in culture in the
absence of complex and undefined biological fluids (for
example, serum) has long been a major obstacle in understanding the physiology of these cells. Long-term culture
systems to proliferate MeSCs and NSCs were established
(Brannon et al., 2000, Neuroreport 11: 1123-8). The ability of
multipotent human NSCs to expand in vitro produces wellcharacterized material for biological research. As grown in
ling term culture, NSCs are differentiated into bIII-tubulinand glial fibrillary acidic protein (GAFP)-immunopositive
cells (Brannon et al., 2000, Neuroreport 11: 1123-8). After
three years of in vitro expansion, such human NSCs remain
capable of producing neurons and glia on differentiation
(FIG. 6(I)) under non-serum basal media conditions, indicating the multipotency of these cells, thus demonstrating that
this culture system is optimal to maintain NSCs and to investigate their biology. NSCs were also differentiated in coculture with an oxidatively damaged human neuronal cell line
(Sy5). The overnight culture of Sy5 cells were grown in the
media described elsewhere herein, treated with 0.0, 0.01, 0.03
or 0.1 µM H 2 0 2 in NSC media for 15 minutes, thoroughly
washed with DMEM-F12 media, then co-cultured with
NSCs. The results (FIG. 6(II)) indicate that the can be differentiated into neurons and astrocytes by responding to damaged neuronal cells even after lengthy in vitro expansion.
The fate of stem cells is greatly influenced by contextual
cues. Stem cells can respond and differentiate into specific
cell types according to the environmental cues to which they
are exposed. Further, when cells that are incapable of differentiating in response to environmental cues (such as MeSCs
which do not respond to neural environmental cues) are
treated with substituted deoxynucleotide or deoxynucleosides according to the methods of the invention, they are
rendered capable of so differentiating. They become more
developmentally potent in character. Herein is demonstrated
that neural tissue produces environmental factor(s) that can
initiate neural lineage in MeSCs pretreated with BrdU.
MeSCs were co-cultured with differentiated NSCs after
BrdU treatment (10 µM BrdU for 5 days before co-culture) of
the MeSCs. MeSCs did not differentiate into neurons or glia
(bIII-tubulin and GFAP negative) after use of serum or basal
differentiation conditions (data not shown). NSCs were differentiated in 12-wells tissue culture plates under the basal
media condition; i.e., serum-free basal medium containing
Earle's salt and L-glutamine (Invitrogen) for five days prior to
co-culture. NSCs spontaneously differentiated into mixed
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(Falcon, Franklin Lakes, N.J.) and suspended in the basal
medium over these differentiating NSCs. The ratio ofMeSCs
to NSCs was approximately 1:1. For immunocytochemical
analysis of MeSCs, the culture insert was removed from the
well after seven days of co-culture and the MeSCs were fixed
with methanol for 30 min at -20° C.
Immunocytochemistry: After fixation, MeSCs were briefly
washed three times in PBS, then blocked with 3% donkey
normal serum in PBS containing 0.05% Triton X-100 (PBST)
for 1 hour and incubated with mouse IgG2b monoclonal
anti-human bIII-tubulin, clone SDL3D10 (1:500, Sigma) and
goat anti-human-glial filament protein (GFAP) N-terminal
human affinity purified (1:200, Research Diagnostics Inc.,
Flander, N.J.) overnight at 4° C. The corresponding secondary antibodies were donkey anti-mouse conjugated to
rhodamine and anti-goat IgG (H+L) conjugated to FITC
(Jackson IR Laboratories, Inc.), respectively. Following a
brief PBS washing, secondary antibodies were added at a
1:200 dilution in PBST for a 2 hr incubation at room ternperature (RT) in the dark. The cells were then washed with
PBS and covered with Vectashield with DAPI (Vector Laboratories, Inc., Burlingame, Calif.) for fluorescent microscopic
observation.
Image and data analysis: Digitally-captured images from
fluorescent microscopy of cultured cells can be analyzed by
NIH Image software (NIH) with Cell Scoring, Particle Analysis, and Cell Analysis macros. The number of cells showing
particular antibody markers in the areas of interest can be
counted. In addition, total cell number can be counted by
DAPI nuclei counterstaining and each cell population will be
expressed as a percentage of the total cell number. The results
from each treatment condition can be analyzed by ANOVA
and followed by post-hoc (Fisher's Protected LCD) analysis.

astrocyte staining for GFAP was observed in the CA2 subfield
of hippocampus. MeSCs-derived cells, with BrdU-labeled
nuclei, also were localized to areas undergoing active postnatal neurogenesis, including the Islands of Calleja in the
ventral forebrain and the subependyma of the olfactory bulb.
Without the BrdU-treatment, MeSCs transplanted in an
animal's brain do not exhibit immunoreactivity for the human
bIII-tubulin and human neurofilament, indicating that BrdUtreatment is necessary for differentiation of MeSCs even
though environmental cues also contribute to the induction of
neuronal differentiation of the MeSCs.
These results from in vitro and in vivo tests indicate that
MeSCs overcome their mesenchymal commitment by substituted deoxynucleotide or deoxynucleoside treatment and differentiate into neural lineage cells that are phenotypically
unrelated to their embryonic origin.

Example 3
Neural Differentiation ofMeSCs of the Invention in Mouse
Brain
To test migration and differentiation patterns of BrdUtreated, more developmentally potent MeSCs in vivo, such
MeSCs expanded without differentiation as described above
and labeled by the incorporation of bromodeoxyuridine
(BrdU) into nuclear DNA were injected into the lateral ventricle of mature mice (C57/black).
Four to six weeks after transplantation, mouse brains were
analyzed by immunohistochemistry for human specific bIIItubulin and GFAP, markers for neurons and astrocytes respectively. Migration and differentiation patterns of the transplanted MeSCs were quite similar to our previous results with
NSCs transplanted into the rats. The transplanted MeSCs
with BrdU-immunopositive nuclei differentiated into neurons and astrocytes in the host brain as evidenced by fluorescence microscopy after double staining for bIII-tubulin and
GFAP. MeSC-derived cells are found bilaterally in regions of
cerebral cortex and hippocampus. The transplanted MeSCs
migrated over a long distance from the injection site to their
positional termination. Further analysis with double immunostaining for bIII-tubulin and GFAP revealed that MeSCderived neurons and astrocytes were localized in layer V and
III, respectively, in the cortex (FIGS. 9a,b). These neurons
were characterized by dendrites pointing to the edge of the
cortex, and these neuronal dendrites appeared to be associated with the astrocytes in the layer III of the cortex. Around
the pyramidal cell layer of the hippocampus (FIGS. 9c-h),
neurons were immunopositive for bIII-tubulin and exhibited
morphologies with multiple processes and branches. Strong
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Migration and Differentiation ofMeSC of the Invention After
Transplant into Rat Vitreous Cavity
For transplanting the MeSCs into the vitreous cavity of
rats, cells were cultured with the long-term maintenance
media as described above, containing TGF-b3 (1 ng/ml to 10
micrograms/ml; here 100 ng/ml) and about 2 µM 5-bromo2'-deoxyuridine (BrdU) for 3 days in a 6-well tissue culture
without differentiation before injection.
An injury was intentionally made by a needle while these
cells were injected to facilitate the migration ofMeSCs. After
an injury, 20 µl of cell suspension, containing about 1.5xl 0 5
to 2x 105 cells, was slowly injected into the intravitreous space
of the right eye. The left eye was left intact as a control
without injection. At 30 days post-transplantation, the rats
were sacrificed and their eyeballs were removed whole. Then
these eyeballs were paraffin embedded and sliced into 5 µm
sections. The sections were stained with double-immunofluorescent-cytochemistry using rat anti BrdU (1:600, Accurate Chemical & Scientific Corp.) and mouse anti-rhodopsin
(1:200, Chemicon), and mounted on slides, then coverslipped
using VECTASHIELD mounting medium (Vector) with
DAPI.
FIG. 10 show the immunocytochemistry and in situ hybridization histochemistry (ISHH) of the retinal sections 4 weeks
after transplantation of MeSCs pretreated with BrdU and
TGF-b3. Extensive migration of these cells into the lesioned
area of the retina was found (FIG. lOa), similar to other
researchers, who found migration and incorporation of neural
stem cells into the retina after intraocular injections (Nishida
eta!., 2000, Invest Ophthalmol Vis Sci 41: 4268-74; Kurimoto
et al., 2001, Neurosci Lett. 306: 57-60; War:!Vinge et al., 2001,
Exp. Neural. 169: 1-12). However, for the first time is demonstrated herein that MeSCs incorporated into the photoreceptor layer are in fact able to express opsin immunoreactivity (FIG. lOb), in contrast to previous studies that did not
report such findings (Ibid). Since anti-opsin antibody that
recognized both human and rat op sin protein was used, it was
not determined whether opsin is expressed by the donor (human stem cells) or by the host (rat cells). To overcome this
technical problem, ISHH was conducted as described below
against the human rhodopsin gene-encoding region. The
cloned human rhodopsin gene sequence does not recognize
any other species of opsin genes listed by Genbank: in particular, this sequence does not show a significant similarity to
any DNA sequence found in rat genes (data not shown). Using
the human op sin gene sequence as a DIG-labeled RNA probe,
human opsin expression was detected in the retina following
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human stem cells transplantation (FIG. lOc). These results
indicated that MeSCs pretreated with BrdU and TGF-b3 not
only were incorporated into the rat retina, but they also differentiated into photoreceptor cells. MeSCs that were not
pre-treated with BrdU according to the methods of the invention were not able to migrate and differentiate in a tissueappropriate manner.
Construction of exemplary human-specific opsin riboprobe vectors: A 360 bp fragment of a human-specific
rhodopsin gene sequence (from 6241 bp to 6601 bp of
U49742) was selected. The selected human rhodopsin gene
sequence does not have a significant level of homology with
other rhodopsin genes from other species. In particular, this
sequence does not show a significant similarity to any DNA
sequence found in the rat genome (data not shown). The
selected human-specific rhodopsin gene sequence was amplified from human genome DNA by PCR using a forward
primer (5'-TTCCCAATGAGGGTGAGATT-3'; SEQ ID NO:
1) and a reverse primer (5'-GGAATTTCCCACTCTTTGTT3'; SEQ ID NO: 2). PCR amplification was conducted in 50 µl
volumes containing control human genomic DNA (100 ng,
Invitrogen), 133 amplification buffer (Invitrogen), 40 nM of
each primer, dNTP Mix (250 µM, Invitrogen) and Taq DNA
Polymerase (2.5U, Invitrogen), under conditions of: 95° C.
(30 seconds), 52° C. (30 seconds), and 72° C. (60 seconds) for
30 cycles. The PCR-amplified fragment was ligated into a
TOPO TA cloning in vitro transcription vector (Invitrogen)
after gel purification on 2% agar gel. The plasmid was transformed into E. coli-competent cells (Strategene) and the
clone was confirmed by sequencing the insert.
In situ hybridization histochemistry for human opsin
mRNA in paraffin embedded sections: Digoxigenin-labeled
human opsin-specific riboprobes are made by in vitro transcription. Reactions (20 µl) were performed in a reaction
mixture containing 4 µl of 5xtranscription buffer (USB Corporation), 2 µl of lOxdigoxigenin RNA-labeling mix (0.2
µg/ml, Roche), 1 µl of template DNA (PCR reaction
described above, 100 ng/µl), 2 µl of T7 RNA polymerase
(5U/µl, USB), and 11 µl of molecular biology grade water.
After mixing with a pipette, the reaction mixture was incubated at room temperature for 2 hours. The pro be was purified
by ethanol precipitation and dissolved in 100 µl molecular
biology-grade water. 10 µl ofthis probe solution was used to
make the hybridization mixture. Rat eye sections were deparaffinized with xylene (Fisher) for 5 minutes at room temperature, and rehydrated using a serial concentration of ethanol
(Fisher) and distilled water at room temperature. The sections
were then washed with 0.1 M phosphate-buffered saline
(PBS), pH 7.4, for 15 min at room temperature followed by
incubation with 10 ng/ml of proteinase K (Sigma) for 30
minutes at 37° C. The sections were washed twice in glycine
solution (0.75 g glycine/100 ml of0.1 M PB, pH 7.4) for 5
minutes at room temperature and treated with 13% triethanolamine solution (pH 8.0) containing 2.5% acetic anhydride
for 10 minutes at room temperature. The sections were then
prehybridized with hybridization buffer after 2 washes with
2xSSC (saline-sodium citrate buffer, Sigma, pH 7.0) for 15
minutes each at room temperature (RT). Hybridization buffer
consists of 50% formamide, lxDenhardt's solution, 10%
dextran sulfate (Invitrogen), 4xSSC, 0.25 mg/ml yeast tRNA,
and 0.3 mg/ml herring sperm DNA. Hybridization was done
in the hybridization buffer containing 10 µl of digoxygenin
riboprobe as described above for 18 hours at 60° C. After
hybridization, the sections were washed twice with 4xSSC
buffer, followed by a stringency wash with 50% formamide
and 2xSSC for 30 minutes at 60° C. The sections were washed
twice with RNase buffer (10 mM Tris, pH 8.0, 0.5 M NaCl, 1

mM EDTA) for 10 minutes at room temperature and then
incubated with RNase solution (50 ug/ml of RNase
(Promega) in RNase buffer) for 30 minutes at 37° C. The
sections were washed with serial concentration of SSC buffer
(2x, 0.5x, O.lx) twice for 20 minutes at 60° C., except that the
last wash was done at RT. After rinsing with PBS, the probe
was visualized by immunodetection of digoxygenin with a
primary antibody, sheep anti-digoxigenin (1:500, Roche),
and secondary antibody with fluorescein (FITC)-conjugated
AffiniPure donkey anti-sheep IgG (1 :200, Jackson Laboratories).
Image and data analysis: Digitally-captured images from
the fluorescent microscopy of cultured cells can be analyzed
utilizing NIH Image software (NIH) with Cell Scoring, Particle Analysis, and Cell Analysis macros as described above.
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DNA Methylation and BrdU
Some DNA restriction digestion enzymes are sensitive to
cytosine methylation, and they are unable to cut DNA when
the cutting site includes methylated cytosine. One such
enzyme (HpaII) was used to investigate whether BrdU treatment altered the enzyme-cutting pattern by modification of
DNA methylation. Genomic DNA from human MeSCs
treated with 0 µM, 1 µM and 10 µM BrdU for 72 hr was
digested and analyzed by polyacrylamide gel electrophoresis
on 0.6% polyacrylamide gel. In a dose-dependent fashion the
size of the DNA fragments produced by digestion increased,
indicating that BrdU prevented enzyme digestion (FIG. 11).
This result may be explained by the alteration of DNA methylation status in MeSC by the BrdU treatment. Other substituted deoxynucleotide or deoxynucleoside compounds are
suitable replacements for BrdU.
Example 6
Transplantation of More Developmentally Potent Cells of the
Invention to Nucleus Basalis Magnocellularis (NBM) Lesion
RatModel
Stem cell transplantation strategies are advocated inAlzheimer' s disease (AD) neuroregeneration therapy. Basal cholinergic neurons, which are selectively degenerated in AD,
extend long projections into the cortex and hippocampus. An
open question for neuroreplacement treatment for AD is
whether these degenerating cholinergic cells can be replaced
by the transplantation of stem cells. To answer this question,
more developmentally potent cells of the invention were
transplanted into nucleus basalis magnocellularis (NBM)
lesion model rats. The lesions were induced either by an
injection of ibotenic acid or by anti-NGF receptor antibody
conjugated with saporin (Advanced Targeting System, San
Diego, Calif.). Cells prepared according to the invention were
simultaneously injected into the contralateral side of the lateral ventricle (Qu, 2001) of the NBM-lesioned animal. Four
weeks after the surgery, the brain was examined by immunohistochemistry. Many GFAP-positive cells were detected in
the lesioned area, but they were not BrdU-positive, indicating
astrocytes activation in this area. BrdU-positive cells with
ChAT or bIII-tubulin immunoreactivity were found in the
lesion site, indicating that more developmentally potent cells
of the invention migrated from the contralateral ventricle to
the lesion site and had differentiated into cholinergic and
other neuronal cells. These neuronally differentiating cells
were neurons that appeared rather morphologically premature. Our results indicate a positive study of neuroreplacement treatment for cholinergic neurons in AD.
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Transplantation of cells of the invention: Male SD rats
were deeply anesthetized with sodium pentobarbital (50
mg/kg, i.p.). Using bregma as a reference point, about lxl0 5
cells of the invention were collected and slowly injected into
the right lateral ventricle(AP 1.4; ML3.3; and DY 4.5mm)of
the rat brain using a stereotaxic apparatus (Devid Kopff).
Cholinergic lesions induced by 192-IgG-saporin conjugate: Male Sprague-Dawley rats, 4-months-old, were anesthetized with 50 mg/kg pentobarbital and mounted in a stereotaxic apparatus (David Kopf). Unilateral NBM injections
of the 1 µg/2 µ1192-IgG-saporin conjugate toxin (ina vehicle
of sterile filtered 200 mM phosphate buffer (pH 7.4)) were
performed using a microsyringe. The NBM was stereotaxically localized using the following coordinates: AP=-2.3 mm
from bregma, ML=±3.7 mm, 7.5 mm below dura. The toxin
was delivered over 5 minutes and the needle was left in place
for another 5 minutes following injection.
Immunohistochemistry: Rats were sacrificed by an overdose of anesthesia (sodium pentobarbital, 70 mg/kg, i.p.) and
perfused with phosphate buffered saline (PBS) followed by
4% paraformaldehyde. Brains were removed and placed into
the 4% paraformaldehyde fixative containing 20% sucrose
for overnight. The brains were sliced into 20 µm, coronal
sections using cryomicrotome. The sections were washed
briefly in PBS and pretreated with 1M HCL for 30 minutes at
room temperature (RT) and neutralized with sodium borate
(O. lM, pH 8.0) for 30 minutes, in order to increase the accessibility of the anti-BrdU antibody to the BrdU incorporated in
the cell nuclei. After rinsing with PBS, sections were transferred to a solution containing 0.25% Triton X-100 in PBS
(PBST) for 30 minutes. Then the sections are blocked in
PBST containing 3% donkey normal serum for 1 hr and
incubated in mouse anti-BrdU (1:200DSHB, Iowa City,
Iowa) or sheep anti-BrdU (l:lOOOJackson IR Laboratories,
Inc. West Grove, Pa.) diluted in PBST overnight at 4° C.
Sections were then washed with PBS and incubated with
mouse IgG2b monoclonal anti-human bIII-tubulin, clone
SDL3D10 (1:500, Sigma), rat IgG monoclonal anti-ChAT
(1:500, Boehringer-Mannheim) and goat anti-human-glial
filament protein, N-terminal human affinity purified (1:200,
Research Diagnostics Inc., Flander, N.J.), respectively, for
overnight at 4 ° C. in the dark. After rinsing in PBS, donkey
anti-mouse, donkey anti-rat, donkey anti-goat or donkey antisheep IgG conjugated with rhodamine or FITC (Jackson IR
Laboratories, Inc.) were added at 1:200 dilution in PBST for
2 hours at RT in the dark. Sections were then washed with
PBS thoroughly before mounting on glass glides. The sections were coverslipped with mounting media containing
DAPI for nucleus counter staining.
Increased GFAP immunoreactivity in the NBM was
observed 4 weeks after saporin lesion. (FIG. 12. Green:
GFAP; Blue: DAPI). Choline acetyltransferase (ChAT)
immunoreactivity was also observed in BrdU positive cells in
the lesion site (FIGS. 13a-c. Green: ChAT; Red: BrdU; Blue:
DAPI), indicating replacement oflesioned cells by the transplanted cells of the invention. Further, ChAT immunoreactivity was observed n human nuclei positive cells in the lesion
site. (FIG. 13d. Green: ChAT; Red: human nuclei; Blue:
DAPI). Human nuclei immunoreactivity-positive cells were
observed in the lesion area (FIG. 14. Red: human nuclei;
Blue: DAPI) and GFAP and human nuclei immunoreactivity
were observed in the lesion site. (FIG. 15. Green: GFAP; Red:
human nuclei; Blue: DAPI). A large number of transplanted
cells migrated to the lesion site and differentiated into rather
mature neurons and glia 4 weeks after transplantation. The

lesion appears to attract the cells of the invention, indicating
a possible release of the migration factor(s) from the lesion
site.
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Expression ofReelin, Alpha 3-Integrin, and DAB-1 in Stem
Cells
To investigate the function of reelin in cell culture, human
MNSCs were differentiated under serum-free conditions.
Previously, human MNSCs were observed not only survive at
least three weeks in serum-free conditions, but to fully differentiate into b3-tubulin, GFAP, and 04 immunopositive
cells.
Reelin may serve to regulate migration based on the finding
that exposure to recombinant reelin causes the differentiating
human MNSCs cultures to immediately retract their processes back to the cell cluster. The cell cluster is composed of
undifferentiated cultured cells with migrating and differentiating cells forming the leading outer processes.
To assess the presence of reelin and responsive mechanisms in HNSCs, immunocytochemistry and Western blot
analysis were performed using antibodies recognizing reelin
alpha 3-integrins (a3-integrins) and DAB-1. Five days after
differentiation, reelin immunoreactivity (green) was present
mainly on small bipolar cells suggestive of neurons, and very
little reelin immunoreactivity was detected in GFAP positive
cells (red), which are suggestive of astrocytes (FIG. 16a).
a3-integrin immunoreactivity was also detected in small
bipolar cells but not in GFAP-positive cells, indicating
expression of a3 integrin predominant in neurons (FIG. l 6b),
while in DAB-1, a cytoplasmic adapter protein, immunoreactivity was detected in not only neurons but also in astrocytes
(FIG. 16c). Intracellular distribution ofDAB-1 was higher in
the nucleus and was evenly distributed in the cytoplasm.
Using the electron microscope, a3-integrin immunoreactivity
was observed to be localized on the cell membranes (FIG.
17). In FIG. 16, reelin appears to have been released from
reelin-positive cells and to have reached neighboring cells.
Western blot analysis of samples prepared by immunoprecipitation from differentiated HNSCs with monoclonal antibody (Reelin 142) showed reelin, a3 integrin, and DAB-1
immunopositive bands (FIG. 18), indicating that these molecules interact with each other in the reelin signaling cascade,
and that reelin released from a population of cells may coordinate movement of these cells as a regulator of stem cell
biology.
Since reelin immunoreactivity was also present in the cell
cluster before differentiation (FIG. 17d), it is possible that
HNSC movement is organized by the active production of
reelin within the center of the cluster, which may also serve to
prevent a rapid state of differentiation. The cells located on
the outer edge of the cluster, on the other hand, may be
exposed to lower concentrations of reelin. Consequently,
these cells are less restricted and begin to differentiate and
migrate out from the center of the cluster. Since undifferentiated stem cells express reelin, reelin expression was also
investigated in mouse embryonic stem cells. A subpopulation
of embryonic stem cells in three days old embryos expressed
reelin, indicating that reelin is a factor that regulates stem cell
biology because it is expressed in embryonic stem cells
before Cajal-Retzius cells begin to produce reelin during
corticogenesis.
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Example 8

type of shrunken morphology that cells undergoing apoptotic
cell death display. To further assess the type of cell death, a
TUNEL assay was used to detect in situ DNA fragmentation,
an early marker of apoptosis, in HNSCs different!~ted in
serum or in serum-free media. Many cells were positive for
the TUNEL signal under serum-free differentiation conditions and displayed soma! shrinkage followed by cell detachment from the culture plates. In contrast, only a few TUNELpositive cells were detected under serum differentiation
conditions (FIG. 24). Since neurons are known to undergo
apoptosis after serum deprivation, and B27 is reported ~o
prevent neuronal death in cultured cortical .tis.sue, apo~t.os1s
of human MNSCs in serum-free differentrnt10n cond1t10ns
may be due to supplement deprivation. Our time lapse video
microscopic study of human MNSCs plated in ~erum-~ree
unsupplemented media for 1 DIV revealed that d1fferentrnting human MNSCs appear to reach out to the nearby morphologically apoptotic cells described.a~~ve (FIG. 25). These
results suggest that human MNSCs 1mtrnlly become apoptotic under serum-free differentiation conditions and subsequently express migration and/or differentiation factors to
influence the fate of neighboring cells.
A combination of immunocytochemistry with 22Cl 1,
which is a monoclonal antibody recognizing the N-terminal
end of APP and the TUNEL assay revealed a marked increase
ofAPP immunoreactivity in the TUNEL-signal-positive cells
under serum-free differentiation conditions compared to the
background levels of APP found in neighboring hu~an
MNSCs (FIG. 26). This result not only confirms p~ev10us
findings that APP expression is elevated in the apoptot1c cell.s,
but more importantly suggests that one factor produced m
apoptotic cells to influence the differentiation of neighboring
cells could be the N-terminal fragment of APP.

. .
Transplantation of Stem Cells to Reeler Mice .
The effects of reelin on the migratory and d1fferentrnt10n
pattern of human MNSCs in vivo were investigated. Hu~an
MNSCs were expanded without differentiation as descnbed
above and treated by the incorporation of BrdU into nuclear
DNA. Then, human MNSCs were injected in to the lateral
ventricle of wild (c57 /black) and reeler mice at one month
old. Brain from these animals were investigated by immunohistochemistry for bIII-tubulin, GFAP, and BrdU four weeks
after injection. Wild-type animals showed diff~re~tiation and
distribution patterns of transplanted FINSCs s1m1lar to those
found in previous rats transplantation studies (FIG. 20).
Human MNSCs transplanted in reeler mice did not successfully migrate into the host brain. In the cortex, a few
GFAP-positive cells were detected (FIG. 21d), but bIII-tub1;1lin positive HNSCs were not present (FIG .. 2~a ) .. bIII-_tubu~m
positive human MNSCs found near the mJect10n site displayed an unusual morphology (FIG. 21b). Reelin p~sitive
human MNSCs showed a trained migration pattern m the
white matter of the cortex (FIG. 21.1), indicating that environmental reelin is necessary for the migration ofNSCs and that
the cells expressing reelin have potential to migrate in reeler
mice.
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Example 9
Analysis of Stem Cell Populations in Reeler Mice
Since the examples described herein indicate poor stem
cells migration patterns in reeler mice, we suspect~d a sii:iiiar
migration pattern for endogenous stem cells. To mvestJgate
the endogenous stem cell population in reeler mice co.mpared
with the wild-type mice, BrdU (100 mg/kg/day) was mJected
into reeler homozygous, reeler heterozygous, and wild-type
mice for four days. The hippocampus and SVZ of these mice
were immunofluorescent stained for BrdU. Mouse NSCs,
which proliferated during the injection period, incorporate.d
BrdU into their nuclei, which can be detected as BrdU pos1tive cells. Significantly reduced BrdU positive cells were
found in the hippocampus of both reeler homozygous and
heterozygous mice compared with wild-type mice (FIG. 22),
while stem cell populations in SVZ of reeler homozygous and
heterozygous mice were preserved (FIG. 22), indicating. that
the proliferation of stem cells was not affected, but the m1gr~
tion of the stem cells from SVZ to hippocampus was dramatically diminished by the lack ofreelin.
Example 10
Isolation of Stem Cells from the Reeler Mice
NSCs were isolated from adult mice (4 months old, C57I
black) as responders for bFGF. They were expanded in vitro
using the same media as used for human MNSC cultures. The
cells formed clusters (FIG. 23a), which are similar to the ones
formed by the NSCs. These NSCs were capable of producing
neurons and astrocytes by differentiation after three months
of in-vitro expansion (FIG. 23b).
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Inhibition of Human MNSC Differentiation under Non-Serum Conditions by an Antibody Against APP
To investigate the involvement of the secreted APP fragment during differentiation, HNSCs were co-incubated in
serum or serum-free differentiation conditions for three days
with various 22Cl 1 concentrations. The addition of22Cl 1 to
the culture dose-dependently (125, 250, 500 µg/ml) inhibited
differentiation of human MNSCs under serum-free unsupplemented conditions (FIG. 27). In contrast, 22Cl 1 treatment
did not inhibit the differentiation of human MNSCs under
serum differentiation conditions (data not shown). These
results suggest that APP is involved in the differentiation of
human MNSCs under serum-free differentiation conditions
while differentiation factors independent of the APP pathway
exist under serum differentiation conditions.
Example 13
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Example 11
Characteristics of Differentiated Human MNSCs under NonSerum Condition
During the early stages (1-3 days in vitro, DIV) of serumfree differentiation, many human MNSCs exhibited the same
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Treatment of HNSCs with Secreted-Type APP
To investigate whether 22Cl 1-induced inhibition of
human MNSC differentiation occurs through the sequestering of sAPP or by blocking the N-terminal domain of APP on
the membrane of differentiating cells, human MNSCs were
treated with exogenous sAPP. Recombinant human sAPP was
produced in yeast, which contains 95% sAPP695T (e~~ing at
amino acid 505 of 695) and 5% sAPP695. The add1t10n of
recombinant sAPP to the cell culture media dose-dependently
(25, 50 and 100 ng/ml) differentiated human MNS~s (FIG.
28) under serum-free differentiation conditions. This result
suggests that the sequestering of sAPP by 22Cl 1 may play a
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role in inhibiting HNSC differentiation. sAPP treatment did
not increase the TUNEL signal in human MNSCs (data not
shown).
The cell population of sAPP-treated human MNSCs at 5
DIV under the serum-free differentiation condition was also
characterized by double immunofluorescence labeling of
GFAP and bIII tubulin (FIG. 29). Treatment with sAPP dose
dependently (25, 50, 100 ng/ml) increased the population of
GFAP positive cells from an average of 45% in controls (no
sAPP) to an average of83% using the highest concentration
ofsAPP (lOOng/ml at 5 DIV). Higher doses ofsAPP (50 and
100 ng/ml) dose-dependently decreased bIII-tubulin-positive
neurons in the total population of differentiated human
MNSCs, from an average of 51 % in controls to an average of
13% in the highest concentration of sAPP (FIG. 30). These
results indicate that sAPP released from dying cells promotes
differentiation of human MNSCs while causing gliogenesis
at higher doses. sAPP can influence the cell fate decision of
human MNSCs by increasing glial differentiation; sAPP may
cause an accelerated migration of astrocytes resulting in
increased levels of glial cell differentiation; and high concentrations of sAPP may reduce or eliminate the human MNSC
population differentiating into neurons, since high APP
expression in neuronal cell lines have been reported to cause
apoptotic cell death by caspase 3 activation.

described above. Cells distributed bilaterally in the singular
and parietal cortexes (layer II, IV and V) (FIG. 32a) and
hippocampus (pyramidal cell layer) (FIG. 35c) were
intensely and extensively immunopositive for BrdU and
human bIII-tubulin. The transplanted human MNSCs also
differentiated into GFAP-immunopositive cells that co-localized with the neuronal fibers of layer III in the cortex (FIG.
32e). These morphologies and distributions ofbIII-tubulinor GFAP-positive cells were not detected in wild-type control
mice that did not receive human MNSC transplantation.
Although human MNSCs transplanted into the APP knockout mice also differentiated into bIII-tubulin and GFAP-positive cells, distribution and migration patterns were not symmetric and the number of the differentiated cells was lower
than in compared to control wild-type mice. Despite the
rather uniform bIII-tubulin positive cell distribution and
structure in the hippocampus of APP knockout mice (FIGS.
32dj), bIII tubulin positive HNSCs were scarcely distributed
in the cortex and lacked apical dendrites (FIG. 3 2b). Although
it is conceivable that the APP expression of transplanted
human MNSCs may partially compensate for the APP deficit
in the host brain, it is quite apparent that such levels of
expression are negligible and that the absence of environmental APP clearly alters the migration pattern of transplanted
HNSCs. These results indicate that there were insufficient
environmental factors to properly guide the migration and
differentiation of HNSCs in APP knockout mice, and that
environmental or secreted APP may be important factors in
regulating cell fate and migration of human MNSCs in vivo.
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Example 14
Effect of APP Transgene to Human MNSCs
To confirm the glial differentiation promoting effect of
sAPP, human MNSCs were transfected with manmialian
expression vectors containing genes for either wild-type APP
or sAPP and differentiated under serum-free unsupplemented
conditions. Human MNSCs transfected with wild-type APP
revealed a significantly higher level of glial differentiation
compared with human MNSCs transfected with the vector
alone at 5DIV (FIG. 31). These results indicate that in addition to the excess of sAPP, wild-type APP over-expression
can also induce glial differentiation of HNSCs. This finding
may have relevance in Down Syndrome (DS), a chromosomal
abnormality resulting in trisomy 21. In addition to its characteristic physical manifestations, DS patients often exhibit
early-onset AD. Since the APP gene is also located on chromosome 21, the increase of APP gene expression by trisomy
21 may explain the excess amount of APP in the brain. It has
been suggested that APP plays a role in neuronal development
and that the earlier appearance of AD in adult DS patients is
associated with an abnormal regeneration process related to
aging.
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Example 15
Transplantation of HNSCs to APP Knockout Mice
The regulatory effect of APP on human MNSCs biology in
vivo was further investigated by transplanting HNSCs into
the brains of APP knockout mice.
To differentiate between host and transplanted cells,
human MNSCs were labeled in vitro by the incorporation of
bromodeoxyuridine (BrdU) into the DNA before transplantation. These labeled cells (about 105 ) were subsequently
injected unilaterally into the cerebral lateral ventricle of c57I
black wild-type and APP knockout mice at 2 months of age.
Immunohistochemical examination of wild-type brain sections four weeks after transplantation revealed migration and
differentiation patterns similar to the previous study with
human MNSC transplantation to aged, memory-impaired rats
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Analysis of Stem Cell Populations in APP Knockout Mice
Since the results set forth above indicated inadequate stem
cells migration patterns in APP knockout mice, a similar
migration pattern was expected for endogenous stem cells. To
investigate this, the endogenous stem cell population in APP
mice were compared with wild-type mice. BrdU (100 mg/kg/
day) was injected into APP knockout and wild-type mice for
four days. The hippocampus and SVZ of the test mice were
immunofluorescently stained for BrdU. Mouse NSCs, which
proliferated during the injection period, incorporated BrdU
into their nuclei, which can be immunofluorescently detected.
BrdU-positive cells in the hippocampus of APP knockout
mice were reduced compared with wild-type mice (FIG. 33);
whereas, stem cell populations in SVZ ofAPP knockout mice
were preserved (FIG. 33), indicating that the proliferation of
stem cells was not affected, but the migration of stem cells
from SVZ to the hippocampus was decreased by the lack of
APP.
It should be understood that the foregoing disclosure
emphasizes certain specific embodiments of the invention
and that all modifications or alternatives equivalent thereto
are within the spirit and scope of the invention as set forth in
the appended claims.
We claim:
1. Developmentally potent mesenchymal stem cells prepared according to a method comprising contacting mesenchymal stem cells with an effective amount of substituted
deoxynucleotide or deoxynucleoside for an effective period,
further comprising the step of co-culturing the mesenchymal
stem cells contacted with substituted deoxynucleotide or
deoxynucleoside with neural-lineage cells or media conditioned with neural-lineage cells, wherein the substituted
deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal
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stem cells capable of differentiating to cells of neural lineage,
with or without further comprising the step of contacting the
mesenchymal stem cells with heparin, a growth factor or
substituted deoxynucleotide or deoxynucleoside in an
uncoated flask or a flask that has been treated to repel the cells,
and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.
2. Developmentally potent mesenchymal stem cells of
claim 1, wherein the cells form a cluster of two or more cells.
3. Developmentally potent mesenchymal stem cells of
claim 2, wherein the cluster of cells comprise less than about
50 percent redifferentiated cells.
4. Developmentally potent mesenchymal stem cells of
claim 2, wherein the cluster of cells comprise less than about
25 percent redifferentiated cells.
5. Developmentally potent mesenchymal stem cells of
claim 2, wherein the cluster of cells comprise less than about
10 percent redifferentiated cells.
6. Developmentally potent mesenchymal stem cells of
claim 2, wherein the cluster of cells comprise less than about
5 percent redifferentiated cells.
7. Developmentally potent mesenchymal stem cells of
claim 2, wherein the cluster of cells comprise less than about
1 percent redifferentiated cells.
8. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier or excipient and developmentally potent mesenchymal stem cells prepared according to
the methods of claim 1.
9. A cellular preparation comprising, as an active ingredient, developmentally potent mesenchymal stem cells of claim
1, 2, 3, 4, 5, 6 or 7.
10. A pharmaceutical composition comprising developmentally potent mesenchymal stem cells of claim 1, 2, 3, 4, 5,
6 or7.
11. The pharmaceutical composition according to claim 10
further comprising a pharmaceutically acceptable carrier.
12. A cell having a second developmental potential phenotype prepared according to a method comprising the steps of:
a) contacting a cell of a first developmental potential phenotype with an effective amount of substituted deoxynucleotide or deoxynucleoside for an effective period
that causes the cell to change into a second developmental potential phenotype distinct from the first developmental potential phenotype; and
b) co-culturing the substituted deoxynucleotide or deoxynucleoside-contacted cell of a) with neural-lineage cells
or media conditioned with neural-lineage cells,
wherein the first developmental potential phenotype is a
less developmentally potent mesenchymal stem cell;
wherein said second developmental potential phenotype is
a more developmentally potent mesenchymal stem cell
capable of differentiating into a cell of neural lineage;
and
wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine or chlorodeoxyuridine.
13. The developmentally potent mesenchymal stem cells
of any one of claim 1, 2, 3, 4, 5, 6 or 7 wherein the substituted
deoxynucleotide or deoxynucleoside is bromodeoxyuridine.
14. The cell having a second developmental potential phenotype of claim 12 wherein the substituted deoxynucleotide
or deoxynucleoside is bromodeoxyuridine.
15. Developmentally potent mesenchymal stem cells prepared according to a method comprising contacting mesen-

chymal stem cells with an effective amount of substituted
deoxynucleotide or deoxynucleoside for at least three days,
wherein the substituted deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further
comprising the step of contacting the mesenchymal stem cell
with heparin, a growth factor or substituted deoxynucleotide
or deoxynucleoside in an uncoated flask or a flask that has
been treated to repel the cells, and wherein the substituted
deoxynucleotide or deoxynucleoside is bromodeoxyuridine,
bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.
16. Developmentally potent mesenchymal stem cells of
claim 15, wherein the cells form a cluster of two or more cells.
17. Developmentally potent mesenchymal stem cells of
claim 16, wherein the cluster of cells comprise less than about
50 percent redifferentiated cells.
18. Developmentally potent mesenchymal stem cells of
claim 16, wherein the cluster of cells comprise less than about
25 percent redifferentiated cells.
19. Developmentally potent mesenchymal stem cells of
claim 16, wherein the cluster of cells comprise less than about
10 percent redifferentiated cells.
20. Developmentally potent mesenchymal stem cells of
claim 16, wherein the cluster of cells comprise less than about
5 percent redifferentiated cells.
21. Developmentally potent mesenchymal stem cells of
claim 16, wherein the cluster of cells comprise less than about
1 percent redifferentiated cells.
22. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier or excipient and developmentally potent mesenchymal stem cells of claim 15.
23. A cellular preparation comprising, as an active ingredient, developmentally potent mesenchymal stem cells of any
one of claim 15, 16, 17, 18, 19, 20, or 21.
24. A pharmaceutical composition comprising developmentally potent mesenchymal stem cells of any one of claim
15, 16, 17,18,19,20,or21.
25. The pharmaceutical composition according to claim 24
further comprising a pharmaceutically acceptable carrier.
26. A method for making developmentally potent mesenchymal stem cells capable of differentiating to cells of neural
linage, the method comprising the steps of contacting mesenchymal stem cells with an effective amount of substituted
deoxynucleotide or deoxynucleoside for an effective period;
and co-culturing the mesenchymal stem cells contacted with
substituted deoxynucleotide or deoxynucleoside with neurallineage cells or media conditioned with neural-lineage cells,
wherein the substituted deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further
comprising the step of contacting the mesenchymal stem cells
with heparin, a growth factor or substituted deoxynucleotide
or deoxynucleoside in an uncoated flask or a flask that has
been treated to repel the cells, and wherein the substituted
deoxynucleotide or deoxynucleoside is bromodeoxyuridine,
bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.
27. The method of claim 26 wherein the developmentally
potent mesenchymal stem cells form a cluster of two or more
cells.
28. The method of claim 26 further comprising contacting
the mesenchymal stem cells with a growth factor.
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29. The method of claim 28 wherein the growth factor is
fibroblast growth factor, epidermal growth factor or a combination thereof.
30. The method of claim 28 wherein the growth factor is
fibroblast growth factor or epidermal growth factor.
31. The method of claim 28 wherein the growth factor is
fibroblast growth factor.
32. The method of claim 28 wherein the growth factor is
epidermal growth factor.
33. The method of claim 26 further comprising the step of
contacting the mesenchymal stem cells with heparin.
34. The method of claim 26 wherein the mesenchymal
stem cells are obtained from a zygote, blastocyst, embryo,
fetus, infant juvenile or adult.
35. The method of claim 26 wherein the mesenchymal
stem cells are obtained from a human.
36. A method for changing a developmental potential phenotype of mesenshymal stem cells, comprising the steps of
contacting mesenchymal stem cells of a first developmental
potential phenotype with an effective amount of substituted
deoxynucleotide or deoxynucleoside for an effective period
that causes the mesenchymal stem cells to change into a
second developmental potential phenotype distinct from the
first developmental potential phenotype; and co-culturing the
substituted deoxynucleotide or deoxynucleoside contacted
mesenchymal stem cells with neural-lineage cells or media
conditioned with neural-lineage cells, wherein said second
developmental potential phenotype is capable of developing
to cells of neural lineage, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.
37. A method for making developmentally potent mesenchymal stem cells capable of differentiating to cells of neural
Image from mesenchymal stem cells, the method comprising
contacting mesenchymal stem cells with an effective amount

of substituted deoxynucleotide or deoxynucleoside for at
least three days, wherein the substituted deoxynucleotide or
deoxynucleoside-contacted mesenchymal stem cells become
developmentally potent mesenchymal stem cells capable of
differentiating to cells of neural lineage, with or without
further comprising the step of contacting the mesenchymal
stem cell with heparin, a growth factor or substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask
that has been treated to repel the cells, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine,
methyldeoxythymidine, or chlorodeoxyuridine.
38. The method of claim 37 wherein the mesenchymal
stem cells are contacted with substituted deoxynucleotide or
deoxynucleoside in an uncoated flask or a flask that has been
treated to repel the cells.
39. The method of claim 37 wherein the developmentally
potent mesenchymal stem cells form a cluster of two or more
cells.
40. The method of claim 37 further comprising contacting
the mesenchymal stem cells with a growth factor.
41. The method of claim 40 wherein the growth factor is
fibroblast growth factor, epidermal growth factor or a combination thereof.
42. The method of claim 40 wherein the growth factor is
fibroblast growth factor.
43. The method of claim 40 wherein the growth factor is
epidermal growth factor.
44. The method of claim 37 further comprising the step of
contacting the mesenchymal stem cells with heparin.
45. The method of claim 37 wherein the mesenchymal
stem cells are obtained from a zygote, blastocyst, embryo,
fetus, infant juvenile or adult.
46. The method of claim 37 wherein the mesenchymal
stem cells are obtained from a human.
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